

**STANDARD TREATMENT
GUIDELINES
UROLOGY**

**Ministry of Health & Family Welfare
Govt. of India**

Group Head Coordinator of Development Team

Prof. Rajesh Ahlawat

**Chairman,
Department of Urology & Kidney Transplant,
Medanta Medicity**

Reviewed By:

Dr Anup Kumar Gupta

**Head of Department
Department of Urology
VMMC and Safdarjang Hospital,
New Delhi**

HAEMATURIA

Introduction:-

Hematuria is the presence of red-blood cells (RBC) in urine.

- It may be categorized as gross (visible to naked eye) or microscopic (detected in urine microscopy). The recommended definition of microscopic hematuria is three or more red blood cells per high-power field on microscopic evaluation of urinary sediment from two of three properly collected urinalysis specimens.
- It may arise from any part of the urinary tract, from glomerulus to meatal tip and may be characterized as initial, terminal or total, which points to the approximate site of origin (distal to external sphincter, proximal urethra-bladder neck, and bladder and upper tracts, respectively).
- Severity of hematuria bears no relation with the etiology, therefore, its presence must be considered serious unless proven otherwise.

Prevalence:-

The prevalence of asymptomatic microscopic hematuria varies from 0.19 percent to as high as 21 percent any varies widely with different age groups.

Differential diagnosis

Hematuria is a manifestation of a myriad of varied clinical diagnoses ranging from exercise-induced to cancer-related. The differential diagnosis can be classified on the basis of site of origin as shown below:

| Origin | Etiologies |
|-----------------|--|
| Glomerular | Acute glomerulonephritis, lupus nephritis, benign familial hematuria, Berger's disease, Goodpasture's disease, exercise hematuria. |
| Renal | Polycystic kidney disease, Medullary sponge kidney, papillary necrosis, renal infarct, lymphoma, multiple myeloma, amyloidosis, inflammation and infections, vascular malformation |
| Urologic | Neoplasia, calculi, benign Prostatic hyperplasia, urethral stricture, endometriosis, diverticulitis, infection, foreign body, GUTB |
| Adjacent organ | Abdominal aortic aneurysm, appendicitis, infiltrating malignancy |
| Hematologic | Congenital and acquired coagulopathy, therapeutic anticoagulation, sickle-cell disease and trait, sickle-cell thalassaemia, sickle-cell Hemoglobin-C disease |
| Fictitious | Vaginal bleed |
| False hematuria | Food pigments, drug metabolites, malingering |

Diagnosis and evaluation:

Once a patient presents with history of hematuria, first step is detailed history and clinical examination.

1. History should include nature of hematuria whether intermittent / continuous, total / initial / terminal, or episodic.
2. Associated symptoms
 3. passage of stones, tissues, clots; shape of clots (tubular, small).
 4. Lower urinary tract symptoms (poor stream, frequency, urgency, nocturia, incontinence, dysuria, etc.
 5. Pain, location (flank, groin, suprapubic, other), nature and other characteristics.
 6. History of fever, facial puffiness, pedal edema.
7. Medications (e.g. oral contraceptives, analgesics, anticoagulants, others)
8. Co-morbidity like tuberculosis, diabetes mellitus, hypertension,
9. Coagulation disorders and family history of renal disease.
10. General physical examination and a focused examination pertaining to genitourinary system.

Next step is to perform a urine microscopy to confirm presence of RBCs and to rule out other causes of red brown colour in urine;

Dipstick tests commonly available will be positive in presence of RBCs, hemoglobin or myoglobin, therefore not specific for hematuria. Therefore, a positive dipstick must be followed by a microscopy.

Urine analysis:

- Ideally the sample is collected in the lab. rather than brought from home (a urine sample not freshly voided or collected from drainage bag is unreliable for analysis).
- For male and female adults, clean catch mid-stream urine sample should be evaluated. In female the technique is similar but requires more attention as chances of contamination are much higher.
- In children the method is similar for those who can be made to follow the instructions. Otherwise, after cleansing, a sterile plastic bag is placed over penis / vulva. In case the specimen is not satisfactory, suprapubic aspiration may be done (easy in small children because intra-abdominal location of bladder).

One aliquot of the sample is subjected to routine examination (color, transparency, specific gravity, chemical analysis for pH, protein, etc.).

Ten milliliters of the second aliquot of urine is centrifuged at 2000rpm for 5min, and supernatant is discarded.

The sediment is re-suspended, a drop of which is examined under microscope for cells, crystals and casts.

RBCs are easily visible in X400 power. Microhematuria is diagnosed in presence of more than 3 RBCs per high power field in adults and 5 or more in children and in trauma cases. The morphology of RBC as well as presence of RBC clumps and casts should be seen. Phase contrast microscopy is the best way to detect dysmorphic RBCs. Dysmorphic RBCs are suggestive of a renal or glomerular source of hematuria.

Hematuria must be interpreted as part of complete urine analysis, as presence of other anomalies e.g. proteins, casts, crystals and pus cells, etc. may suggest towards diagnosis.

After confirmation of erythrocyturia, the next logical step is to differentiate between:

- Glomerular hematuria (presence of dysmorphic RBC, and RBC casts and clumps and usually associated with proteinuria).
- Nonglomerular hematuria - an ultrasonography of abdomen is the next step to detect any anatomical abnormality in the urinary tract (e.g. stones, renal cysts, renal mass, bladder tumor, prostatomegaly, hydronephrosis, etc.).
- For those with history suggestive of infection and associated pyuria, a urine culture and sensitivity should be done to rule out infection,
- Complete blood count, renal functions, blood sugar and coagulogram (if appropriate), must be done to rule out other causes and as a part of workup for surgery if an abnormality is detected on ultrasonography.

In absence of features of glomerular hematuria, urinary tract infection and USG evidence of renal mass, most patients would require cystourethroscopy. Certain investigations are suggested, before proceeding for the same-

1. Urine cytology for malignancy
2. Urine for AFB
3. Intravenous urography / CT urography.

Management:

After complete evaluation approximately overall, 1/3rd will have origin in kidney and the rest in middle and lower urinary tract.

- a. Further management needed in,
 - b. 25% with urinary tract infection
 - c. 20% will be diagnosed as malignancy (bladder cancer, kidney cancer),
 - d. 20% with urinary stone disease.
 - e. Rest 15% other causes

- f. 20% are diagnosed as benign essential hematuria (of obscure origin) and these require careful follow up.

Treatment is guided by the underlying cause of hematuria.

As general practitioners are the frequently the first contact clinicians, they should perform the initial workup (urine analysis, urine culture, ultrasonography) and based on the presentation and these investigation. Uncomplicated UTIs may be managed at the community level. Others should be referred to appropriate specialist (nephrologists, urologist).

Those with glomerular cause of hematuria (fever , facial puffiness, pedal edema, hypertension and presence of dysmorphic RBCs on microscopy) require a nephrology referral for further diagnosis and management.

Those patients diagnosed with a malignancy/renal stone as the cause, need appropriate urology referral to a higher center for further evaluation and management.


Resources required

1. Facility for routine and microscopy of the urine.
2. Ultrasonography.
3. Microbiological services.
4. Radiological services (preferably with facility of computed tomography).

Suggested reading:

- Adler SG, Fairley K: the patient with hematuria, proteinuria or both, and abnormal findings on urine microscopy. In: Schrier RW (ed) Manual of Nephrology, fifth edition, Philadelphia: Lippincott Williams and Wilkins, 2000, pp: 114-131.
- Dinlenc C, Siroky MB: Hematuria and other urine abnormalities. In: Siroky MB, Edelstein RA, Krane RJ (eds), Manual of Urology: diagnosis and therapy, second edition, Philadelphia: Lippincott, Williams and Wilkins, 1999, pp: 95-105.
- In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds), Campbell's Urology, 8th ed, vol 1, Philadelphia: Saunders, 2002, pp:
- Grossfeld GD, Wolf JS, Litwin MS, Hricak H, Shuler CL, Agerter DC, Carroll P. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy recommendations. Part I: definition, detection, prevalence, and etiology. Urology 2001;57(4)
- Messing EM, Young TB, Hunt VB, Roecker EB, Vaillancourt AM, Hisgen WJ, et al. Home screening for hematuria: results of a multiclinic study. J Urol 1992;148(2 pt 1):289-92.

Suggested algorithm of evaluation of surgical hematuria:



URINARY AND MALE GENITAL TRACT INFECTIONS

Introduction

Infections of the urinary tract pose a serious health problem, also because of their frequent occurrence.

Clinical and experimental evidence support that the ascent of micro-organisms within the urethra is the most common pathway leading to urinary tract infections, especially for organisms of enteric origin (i.e. *Escherichia coli* and other Enterobacteriaceae). This is a logical explanation for the greater frequency of UTIs in women than in men and the increased risk of infection following bladder catheterisation or instrumentation.

Classification of Urinary and Male Genital Tract Infections

For practical clinical reasons, urinary tract infections (UTIs) and male genital tract infections are classified according to entities with predominating clinical symptoms: (1) uncomplicated lower UTI (cystitis); (2) uncomplicated pyelonephritis; (3) complicated UTI with or without pyelonephritis; (4) Urosepsis; (5) urethritis; and (6) prostatitis, epididymitis, orchitis.

Definitions

the definitions of bacteriuria and pyuria are as follows:

Significant bacteriuria in adults:

- $\geq 10^3$ uropathogens/ml of midstream urine in acute uncomplicated cystitis in female;
- $> 10^4$ uropathogens/ml of midstream urine in acute uncomplicated pyelonephritis in female;
- $> 10^4$ uropathogens/ml of midstream urine of women or 10^4 uropathogens/ml of midstream urine in men (or in catheter, urine specimen in women) with complicated UTI.

In a suprapubic bladder puncture specimen any count of bacteria is relevant.

Asymptomatic bacteriuria (ABU)

ABU is defined as two positive urine cultures taken more than 24h apart with 10^5 uropathogens/ml of the same bacterial strain.

Pyuria

The requirement for pyuria is 10 white blood cells per high power field in the resuspended sediment of a centrifuged aliquot of urine or per mm^3 in unspun urine. For the routine, a dipstick method can also be used, including leukocyte esterase test, or nitrite reaction.

Table 1. Classification of prostatitis according to NIDDK/NIH

| | |
|------------|---|
| I | Acute bacterial prostatitis (ABP) |
| II | Chronic bacterial prostatitis (CBP) |
| III | Chronic pelvic pain syndrome (CPPS) A Inflammatory CPPS: WBC in EPS/voided bladder urine-3 (VB³) or semen |
| | B Noninflammatory CPPS: no WBC/EPS/VB3/semen |
| IV | Asymptomatic inflammatory prostatitis |

Diagnosis

Disease history, physical examination and urine analysis by dipstick including white and red blood cells as well as nitrate reaction is recommended for routine diagnosis.

In case of suspicion of pyelonephritis, evaluation of the upper urinary tract may be necessary to rule out upper urinary tract obstruction or stone disease.

Table 2. Recommendations for antimicrobial therapy in urology

| Diagnosis | Most Frequent pathogens | Initial, empiric antimicrobial therapy | Therapy duration |
|--------------------------------------|--------------------------------|---|---|
| Cystitis, acute, Uncomplicated | E.coli | Trimethoprim/ sulfamethoxazole | 3 days |
| | Klebsiella | Fluroquinolone ^a | 3 days |
| | Proteus | Alternatives: | |
| | Staphylococcus | Fosfomycin | 1 day |
| Pyelonephritis, acute, uncomplicated | | Nitrofurantoin | 7 days |
| | E.coli | Fluroquinolone | 7-10 days |
| | Proteus | Cephalosporin Gr. 2b/3a | |
| | Klebsiella | Alternatives | |
| | Other Enterobacteria | Aminopenicillin / BLI | |
| | Staphylococcus | Aminoglycoside | |
| UTI with complicating | E.coli | Fluroquinolone | 3-5 days after defervescence or control/ examination of complicating factor |

| | | | |
|-----------------------------|--|--|---|
| Factors | Enterococcus | Aminopenicillin / BLI | |
| Nosocomial UTI | Staphylococcus | Celphalosporin Gr. 2 | |
| Pyelonephritis, acute, | Klebsiella | Celphosporin Gr. 3 a | |
| Complicated | Proteus | Aminoglycosides | |
| | Enterobacter | In case of failure of initial therapy within 1-3 days or in clinically severe cases: | |
| | Other Enterobacteria | Anti-Pseudomonas active: | |
| | Pseudomonas | Fluroquinolone, if not used initially Acylaminopenicillin/BLI | |
| | (Candida) | Cephalosporin Gr. 3B | |
| | | Carbapenem + Aminoglycoside | |
| | | In case of Candida Fluconazole | |
| | | Amphotericin B | |
| Prostatitis, acute, chronic | E.coli | Fluroquinolone ^a | Acute : 2 weeks |
| Epididymitis, acute | Other Enterobacteria | Alternative in acute bacterial prostatitis | |
| | Pseudomonas | Cephalosporin Gr. 2 | Chronic : 4-6 weeks or longer |
| | Enterococcus | Cephalosporin Gr. 3a/b | |
| | Staphylococcus | In case of Chlamydia or Ureaplasma: | |
| | Chlamydia | Doxycyline | |
| | Ureaplasma | Macrolide | |
| Urosepsis | E.coli | Cephalosporin Gr. 3a/b | 3-5 days after defervescence or control/ elimination of complicating factor |
| | Other Enterobacteria | Fluorquinolone ^a | |
| | After urological interventions - Multiresistant | Anti-Pseudomonas active Acylaminopenicillin/BLI | |

| | | | |
|--|--------------|-----------------|--|
| | pathogens: | | |
| | Proteus | Carbapenem | |
| | Serratia | Aminoglycosides | |
| | Enterobacter | | |
| | Pseudomonas | | |

a Fluroquinolone with mainly renal excretion; BLI= B- lactamase inhibitor.
B 1st, 2nd and 3rd generation respectively (3*a* - without; 3*b* - with anti-Pseudomonas activity)

Treatment

Treatment of UTI is dependent on a variety of factors. An overview of most frequent pathogens, antimicrobial agents and duration of treatment in various conditions is given in table 2. Patients with recurrent UTI may be recommended prophylactic treatment. The following regimens have a documented effect in preventing recurrent UTI in women (table 3).

Table 3. Antimicrobial regimens for prevention of acute uncomplicated urinary infection in women

| Agent | Dose |
|--------------------------------------|-------------------|
| Standard regimens (taken at bedtime) | |
| Trimethoprim / sulfamethoxazole | 40/200mg/day or |
| | 3 times weekly |
| Trimethoprim | 100mg/days |
| Nitrofurantoin | 50mg/day |
| Others | |
| Cephalexin | 125 or 250 mg/day |
| Norfloxacin | 200 mg/day |
| Ciprofloxacin | 125 mg/day |

Special situations:

- UTI in pregnancy. Asymptomatic bacteriuria is treated with a 7 day course based on sensitivity testing. For recurrent symptomatic infections, either cephalexin 125-250 mg/day or nitrofurantoin 50 mg/day may be used.
- UTI in postmenopausal women. In women with recurrent infection intravaginal estriol is recommended. If this does not work, in addition antibiotic prophylaxis is indicated.

- UTI in children. Treatment period should be extended to 7-10 days. Tetracyclines and fluoroquinolones should not be used due to effects on teeth and cartilage.
- Acute uncomplicated UTI in young men. The treatment should last at least 7 days.
- UTI in diabetes mellitus and renal insufficiency. After treatment, a prophylactic regimen may be recommended afterwards.
- Complicated UTI due to urological disorders. The underlying disorder must be managed if permanent cure is to be expected. In order to avoid inducing resistant strains, treatment should be guided by urine culture whenever possible.
- Sepsis syndrome in Urology (urosepsis).

Patient with UTI may develop sepsis. Early signs of systemic inflammatory response (fever or hypothermia, tachycardia, tachypnea, hypotension, oliguria, leukopenia) should be recognized as the first signs of possible multiorgan failure. In conjunction with appropriate antibiotic therapy, life supporting therapy in collaboration with an intensive care specialist may be necessary. Any obstruction in the urinary tract needs to be drained.

Follow-up of patients with UTI

for follow-up after uncomplicated UTI and pyelonephritis in women, a urinalysis by dipstick is enough for routine use.

In women who will have recurrence within 2 weeks, repeated urinary culture with antimicrobial testing and evaluation of the urinary tract is recommended.

In the elderly, newly developed recurrent UTI may warrant a full evaluation of the urinary tract.

In men with UTI, a urologic evaluation should be done when the patient is in adolescence, in cases with recurrent infection and in all causes with pyelonephritis. Also patients with prostatitis, epididymitis and orchitis should follow these recommendations.

In children, investigations are indicated after two episodes of UTI in girls and one episode in boys. Recommended investigations are ultrasonography of the urinary tract supplemented by voiding cystourethrography.

Urethritis

Symptomatic urethritis is characterized by dysuria and purulent discharge

Diagnosis

The Gram stain of secretion or urethral smear showing more than 5 leukocytes per high power field (HPF) (1,000) and eventually gonococci located intracellularly as Gram-negative diplococci indicate a pyogenic urethritis. A positive leukocyte

esterase test or more than 10 leukocytes per high-power field (400) in the first voiding urine specimen are diagnostic.

Therapy

The following guidelines for therapy comply with the recommendations of the Centre for Disease Control and Prevention (1998).

For the treatment of gonorrhoea the following antimicrobials can be recommended:

Cefixime 400 mg orally
As a single dose

Ceftriaxone 250 mg i.m.
As a single dose

(i.m. with local anaesthetic)

Ciprofloxacin 500 mg orally
as a single dose

Ofloxacin 400 mg orally as
single dose

As gonorrhoea is frequently accompanied by chlamydial infection, an antichlamydial active therapy should be added. The following treatment has been successfully applied in *C. trachomatis* infections :

First choice

Azithromycin
1 g (=4 caps.@250 mg) orally
as single dose

Doxycycline
10 mg 2 times daily orally for 7 days

if therapy fails, one should consider infections by *T. vaginalis* and / or *Mycoplasma*, which can be treated with a combination of metronidazole (2 g orally as single dose) and erythromycin (4 times daily 500 orally for 7 days).

Second choice

Erythromycin
500 mg orally 4 times daily for 7 days

Ofloxacin
200 mg orally for 7 days

Prostatitis, Epididymitis and Orchitis

Prostatitis

Treatment

- g. Acute bacterial prostatitis can be a serious infection and parenteral administration of high doses of bactericidal antibiotic such as aminoglycosides and a penicillin derivative or a 3rd generation cephalosporin are required until defervescence and normalization of infection parameters. In less severe cases a fluoroquinolone may be given orally for at least 10 days.
- h. In chronic bacterial prostatitis and chronic inflammatory pelvic pain syndrome, a fluoroquinolone or trimethoprim should be given orally for 2 weeks after the initial

diagnosis. Then the patient should be reassessed and antibiotics only continued if pretreatment cultures were positive or if the patient reports positive effect of the treatment. A total treatment period of 4-6 weeks is recommended.

Epididymitis, Orchitis

The majority of cases of epididymitis are due to common urinary pathogens. Bladder outlet obstruction and urogenital malformations are risk factors for this type of infection.

Treatment

Prior to antimicrobial therapy a urethral swab and midstream urine should be obtained for microbiological investigation. Fluoroquinolones, preferably those which react well against *C. trachomatis* (e.g. ofloxacin, levofloxacin) should be first choice drugs because of their broad antibacterial spectra and their

Table 4. Recommendations for perioperative antibacterial prophylaxis in urology

| Procedure | Most common pathogens (s) | Antibiotic(s) of choice | Alternative antibiotic(s) | Remarks |
|--|---|--|---|---|
| Open operations urinary tract including bowel segments | Enterobacteria Enterococci Anaerobes Wound infection: Staphylococci | Aminopenicillin + BLI Cephalosporin 2 ⁰ + Metronidazole | In high-risk patients: Cephalosporin3 Acylaminopenicillin + BLI | In all patients |
| Urinary tract without bowel segments | Enterbacteria Enterococci Wound infection: staphylococci | Fluoroquinolone Cephalosporin 2 ⁰ Aminopenicilin +BLI | in high-risk patients: Cephalosporin3 Acylaminopenicillin + BLI | in patients with increased risk of infection |
| Implant / prosthesis: penis, sphincter Reconstructive genital operation | Staphylococci Staphylococci | Cephalosporin 1 ⁰ /2 ⁰ Cephalosporin 1 ⁰ /2 ⁰ | | in all patients in secondary operations & in patients with increased risk of infection |
| Other interventions outside of the | Staphylococci | Cephalosporin 1 ⁰ /2 ⁰ | | in patients with increased risk of infection |

| | | | | |
|---|--|--|---------------------------------|--|
| urinary tract | | | | |
| Endoscopic – instrumental operations Urethra, prostate, bladder, ureter, kidney, incl. percutaneous litholapaxy and ESWL | Enterobacteria Staphylococci Enterococci | Fluoroquinolone Aminopenicillin + BLI Cephalosporin 2 ⁰ Fosfomycin Trometamol | Cotrimozazole Aminoglycoside | In patients with increased risk of infection |
| Diagnostic intervention Transrectal biopsy of the prostate (with thick needle) | Enterobacteria Enterococci Anaerobes Streptococci Enterobacteria | Fluoroquinolonea Aminopenicllin + BLI Cephalosorin 2 ⁰ + Metronidazole Fluoroquinolonea | Aminoglycoside Cotrimozazole | In all patients |
| Perineal biopsy of the prostate, urethrocystosc opy, ureterorenosco py, percutaneous pyeloscopy, laparoscopic procedures | Enterococci Staphylococci | Aminopenicillin + BLI Cephalosporin 2 ⁰ | Cotrimoxazole | In patients with increased risk of infection |

BLI = B- Lactamase inhibitor, *ESWL*- extracorporeal shock-wave lithotripsy. 1⁰,2⁰,3⁰ = 1st, 2nd, 3rd generation respectively.

11. Fluroquinolone with sufficient renal excretion

Favorable penetration into the tissues of the urogenital tract. In case *C. trachomatis* has been detected as etiologic agent, treatment could also be continued with doxycycline 200 mg/day for a total treatment period of at least 2 weeks. Macrolides may be alternative agents. In case of *C. trachomatis* infection, the sexual partner should be treated as well.

Antibiotics and α Blockers in combination

Urodynamic studies have shown increase urethral closing pressure in patients with chronic prostatitis. A combination treatment of α blockers and antibiotics is reported to have a higher cure rate than antibiotics alone in inflammatory CPPS. This is a treatment option favored by many urologists.

In general, surgery should be avoided in the treatment of prostatitis patients except for drainage of prostatic abscesses.

Perioperative Antibacterial Prophylaxis in Urological Surgery

The main aim of antimicrobial prophylaxis in urology is to prevent symptomatic / febrile genitourinary infections, such as acute pyelonephritis, prostatitis, epididymitis and urosepsis as well as serious wound infections.

Antibiotic prophylaxis is recommended only for a maximum of 24 hours after surgery in most situations. More rampant use leads to antibiotic resistance and places an additional economic burden. Prophylaxis does not substitute for poor surgical asepsis.

Suggested reading:

- Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29: 745–58.
- Huang ES, Stafford RS. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Archives of internal medicine 2002; 162: 41–7.
- O’Connor PJ, Solberg LI, Christianson J, Amundson G, Mosser G. Mechanism of action and impact of a cystitis clinical practice guideline on outcomes and costs of care in an HMO. The Joint Commission journal on quality improvement 1996; 22: 673–82.
- Stamm WE. Evaluating guidelines. Clin Infect Dis 2007; 44: 775–6.
- Mavromanolakis E, Maraki S, Samonis G, Tselentis Y. Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections. J Chemother 1997; 9: 203–7.
- Sullivan A, Edlund C, Nord C. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1: 101–14
- Grabe M, Bishop MC, Bjerklund-Johansen TE, et al. Guidelines on urological infections. In EAU Guidelines edition presented at the 25th EAU Annual Congress, Barcelona 2010. ISBN 978-90-79754-70-0.
- Arredondo-Garcia JL, Figueroa-Damian R, Rosas A, Jauregui A, Corral M, Costa A, et al. Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. J Antimicrob Chemother 2004; 54: 840–3.

STANDARD TREATMENT GUIDELINES

UROLITHIASIS AND URETERIC COLIC

When to suspect /recognize

Introduction:-

American urological association (AUA) has been the frontrunner in formulating guidelines for Urolithiasis since 1991. Since then, editions of guidelines have been published with the 2005 guidelines on staghorn calculus being the latest ⁽¹⁾ The European association of urology(EAU) has published similar guidelines since 2000. The latest updates have been published in 2010⁽²⁾.

The significant differences in the socioeconomic and disease pattern (mode of presentation, stone bulk, health care delivery facilities) for urolithiasis in India make it imperative to formulate our own guidelines.

We have reviewed the literature for drafting the guidelines. The recommendations drawn are largely based on the AUA/EAU guidelines with modifications recommended where appropriate. Indian references have been cited, particularly so, if they are prospective randomized studies and/or metanalysis. Recommendations have been given when adequate literature support is available. The referral criteria are noted when appropriate.

Case definition

The index patients are defined as follows:-

Ureteral stones

A non pregnant adult patient with unilateral ureteral calculi (no renal stones) and normal functioning contralateral kidney, the body habitus, anatomy and medical condition should not preclude the application of any of the available treatment options ⁽²⁾

Staghorn calculi

A staghorn calculi is defined as a stone with central body and at least one calyceal branch. A partial staghorn calculus fills part of the collecting system. A complete staghorn fills all the calyces and the renal pelvis.

Index patient (staghorn calculi):-

Adult with a staghorn stone (non Cystine, non uric acid) who has two functioning kidneys (functioning both kidneys) or a solitary kidney with normal function. The patients overall medical condition, body habitus and anatomy should permit any of the available intervention ⁽¹⁾.

Non staghorn calculi

Any pelvic and /or calyceal calculi which do not fit in the definition of staghorn calculi ⁽²⁾.

Incidence in our country

Although a few studies have been reported for a small group of subjects in screening camps.

The true incidence of urolithiasis in India is still not known. It is commonly seen in western states, hypothetically, attributable to high salinity of water .The presentation of a patient with urolithiasis differs in India. Large stone bulk on presentation is commonly seen in India.

What should be the optimal?

Renal stones

Investigations:-

Imaging is absolutely imperative if, the patient has a solitary kidney or a history of fever. If the diagnosis of stone is in doubt then imaging is mandatory.⁽²⁾ **Excretory urography has been the gold standard in the work up for urolithiasis.** Non contrast computerized tomography(NCCT) scan is quick and safe, contrast free alternative to excretory urography. Randomized studies have shown that non contrast helical CT has similar or superior results to excretory urography in acute flank pain⁽³⁾ **Contrast media should not be given or should be avoided when there is a elevated creatinine level, pregnancy or lactation⁽⁴⁾⁽⁵⁾** Additional information can be gained by contrast enhanced CT scan(CTU), however at the moment **there is no level 1 evidence to suggest that CTU is superior to IVU** in the work up of urolithiasis.⁽⁶⁾ X-ray KUB and ultrasound is used by few clinicians as a measure of preoperative investigations, however this cannot be considered as a standard. These investigations help to plan access and predict the possible success rates.

Recommendation:-Excretory urography is the gold standard in work up for urolithiasis and is mandatory in solitary kidney, history of fever and when the diagnosis is in doubt.

NCCT is the investigation of choice in acute flank pain due to stone.

Analysis of stone composition

Stone analysis is desirable in recurrent stone formers. The preferred analytical procedures are:-

(2)

1) X ray crystallography.

2) Infrared spectroscopy.

The other methods of stone analysis are:-

- 1) Radiographic characteristics of the stone.
- 2) Microscopic examination of the urinary sediments to detect crystals.
- 3) Urine Ph (alkaline in infection stones and acidic in uric acid stones.
- 4) Urine culture.

Special investigations which are ordered on case to case merit are renal scintigraphy, antegrade, retrograde contrast study.

Indications for intervention

The indication for stone removal depends on the size, site and shape of the calculus. The likelihood of spontaneous passage, presence of obstruction should be assessed.

The indications for intervention are:-

- 1) When the stone diameter is more than 7 mm (because of low rate of spontaneous passage).
- 2) When adequate pain relief is not achieved.
- 3) When there is stone obstruction associated with infection.
- 4) Pyonephrosis.
- 5) Obstruction in single kidney.
- 6) Bilateral obstruction.

Recommendation:-For 1, 2 stone removal with or without prior decompression (depending on the clinical situation) is recommended, in situation 3,4,5,6 emergency deobstruction of the collecting system is recommended.

The choice of decompression can be with ureteric stents, percutaneous nephrostomy depending on surgeon preference, expertise and the level of obstruction ^{(7) (8) (9) (10)}

Treatment (including standard operating procedure)

I) Extracorporeal shock wave lithotripsy(ESWL)

The success of lithotripsy depends on the body habitus, location of the stone, efficacy of the lithotripter, stone bulk. **The contraindications for ESWL for renal stones include pregnancy, bleeding disorders, uncontrolled urinary tract infections, morbid obesity, aortic aneurysms close to F1**⁽²⁾

i) Role of stents

Routine use of stents is not recommended for ESWL for renal stones.⁽¹¹⁾

ii) Location of stones

The stone clearance is lower for stones in the lower calyx as compared to anywhere else in the kidney. Various studies have attempted to show the correlation of geometry of the lower calyx to predict the clearance of stone in this location. However the calyceal stone burden is the most important factor in predicting the clearance.

Although there is no critical size, 20 mm should be considered the upper limit for stones in the lower calyx to be recommended for ESWL. The EAU guidelines recommend ESWL as the treatment of choice for renal stones less than 20mm^2 (300mm^2)⁽²⁾. A multicentre trial has compared ESWL and Flexible ureteroscopy for lower calyceal stones. It failed to show any difference in the clearance rates⁽¹²⁾

iii) Total stone burden

It is recommended that stones smaller than 20mm^2 to be treated with ESWL , while for larger stones more than 20mm^2 (300mm^2), PCNL should be considered the treatment of choice.⁽²⁾

iv) Composition and hardness of stone

The **composition of the stone is an important factor for predicting the success rates** of renal calculi. Specific stone compositions have different clearance rates because of the varying

fragility of stones. Cystine stones are harder to fragment, hence cystine stones larger than 15mm should not be treated with ESWL. PCNL would be a good option in these patients⁽²⁾

The **measurement of stone density with NCCT** helps in predicting success rates of ESWL. **Stones with greater than 1000 Hounsfield units (HU) show poor results with ESWL**.⁽¹³⁾⁽¹⁴⁾

v) **ESWL-procedural standard operating protocol**

Simultaneous fluoroscopy and ultrasound monitoring is desirable⁽²⁾ The acoustic coupling between shock head and the skin should be optimal. Ultrasound gel is the best available gel. The ultrasound gel should be applied straight from the container rather than by hand⁽¹⁵⁾⁽¹⁶⁾. Level 4 evidence is available to suggest that proper analgesia results in limited movement and respiratory excursions. **Better fragmentation can be achieved with starting the fragmentation at lower energy setting and then ramping up the power**⁽¹⁷⁾. The manufacturers recommendation regarding the number of shocks and frequency should be followed. The optimal shock wave frequency is 1.0 Hz⁽¹⁸⁾ It is **important to limit the number of shocks and the power**, due to concerns regarding damage to the kidney.

In case of infected stones, **antibiotics should be given according to urine culture sensitivity**, the same should be continued after surgery for 4 days⁽²⁾ Clinical experience suggests that stones in the ureter rather than the kidney should be treated with shorter intervals between sessions.

vi) **Complications**

The complications which are likely to be encountered and which should be counseled to the patient prior to surgery are:-

5. Pain
6. Hydronephrosis
7. Fever
8. Urosepsis

Recommendations:-

It is recommended that stones smaller than 20mm² to be treated with ESWL. Routine use of stents is not recommended for ESWL for renal stones. The contraindications for ESWL for renal stones include pregnancy, bleeding disorders, uncontrolled urinary tract infections, morbid obesity, aortic aneurysms close to F1. Antibiotics should be given according to urine culture sensitivity, the same should be continued after surgery for 4 days. The physicians should refer to the manufacturer recommendation regarding the decision of number, frequency and power of shocks.

II) Percutaneous Nephrolithotomy

Technically most of the renal stones can be managed with a percutaneous nephrolithotomy. However the **usual indications for PCNL are larger than 20mm², staghorn, partial staghorn calculi and stones in patients with chronic kidney disease.**

Standard operating protocol

General anaesthesia is preferable, although studies have demonstrated the utility of regional anaesthesia⁽¹⁹⁾ PCNL has been **performed traditionally in a prone position** however it can technically also be performed in supine position, the advantage of this (supine position) approach is that the retrograde access is easier in supine position, anesthetist has a better control over the airway and simultaneous ureteric and renal stones can be managed without changing the position.⁽²⁰⁾⁽²¹⁾ The access to the collecting system can be gained either **ultrasound guided or fluoroscopy guided depending on the availability of instruments and expertise.** The advantage of ultrasound guided access is the potential to avoid major visceral injuries.⁽²²⁾ The access site should be the posterior calyx. The **tract should be the shortest possible tract from**

the skin to the desired calyx traversing the papilla. Depending on the stone configuration a calyx should be selected (Supracostal, infracostal or subcostal) so that maximum stone bulk can be cleared minimum number of tracts. ⁽²³⁾ Renal tract dilatation either balloon, amplatz or metallic dilators are a matter of surgeon preference and availability ⁽²⁾. In lower polar stones ESWL, PCNL and flexible ureterorenoscopy are competing procedures with different success rates and complications ⁽¹²⁾⁽²⁴⁾. **In complicated cases or when secondary intervention is required a nephrostomy tube which serves the dual purpose of tamponade and a conduit for second look is placed.**

In uncomplicated cases, tubeless percutaneous nephrolithotomy with or without application of tissue sealants is a safe alternative ^{(25) (26)}

i) Complications

The patients should be **counseled regarding the complications** which are likely to be encountered such as life threatening bleeding with a possible need for angioembolisation or even nephrectomy. It may be associated with infective complications leading to urosepsis. **The patients should be counseled regarding the possibility of residual calculi and the consequences thereof.** The procedure becomes challenging in complex stones, although the complications are not specific to them. Such cases should be **identified and managed by experienced surgeons.**

Recommendations

Technically, most of the renal stones can be managed with a percutaneous nephrolithotomy. However the **usual indications for PCNL are larger than 20mm², staghorn, partial staghorn calculi and stones in patients with chronic kidney disease.** The access to the collecting system

can be gained either **ultrasound guided or fluoroscopy guided depending on the availability of instruments and expertise**. Renal tract dilatation either balloon, amplatz or metallic dilators are a matter of surgeon preference and availability. **In complicated cases or when secondary intervention is required a nephrostomy tube which serves the dual purpose of tamponade and a conduit for second look is placed**. In uncomplicated cases, tubeless percutaneous nephrolithotomy with or without application of tissue sealants is a safe alternative.

III) Flexible ureterorenoscopy

Flexible ureteroscopy offers a good treatment option for calculi less than 20mm in size. Due to improved technology and development in accessories and optics the role of flexible ureteroscopy is likely to be expanded in the future. The procedure wherein flexible ureteroscopy is used in the kidney is called as retrograde intrarenal surgery (RIRS). **Flexible URS is not recommended as a first line of treatment for renal calculi. It has been demonstrated as a effective way of treating stones which are refractory to ESWL**. It has also been seen useful when simultaneously used with PCNL, in this way it reduces the number of tracts during the procedure

It is **recommended that sterile urine should be documented** prior to intervention. ⁽²⁷⁾⁽²⁸⁾

Standard technique for flexible ureteroscopy

- Fluoroscopy equipment is advisable in all cases
- Preoperative imaging helps to determine the size and location of the stone.
- The use of safety wire is recommended (0.035 floppy tip) .
- The ureteroscope can be introduced over a guide wire (back loaded) or they may be advanced through a ureteral access sheath.
- Stone extraction blindly without endoscopic vision should not be done

- Small stones can be extracted with baskets or forceps.
- Intracorporeal lithotripsy can be performed with holmium laser. The other alternatives are ballistic, ultrasonic or electrohydraulic lithotripsy. ⁽²⁾ The holmium Yag laser is the preferred modality for flexible ureteroscopy ⁽²⁹⁾
- The stenting after an uncomplicated flexible ureteroscopy is optional. The indications for stenting after completion of URS are ureteral stricture, ureteral injury, solitary kidney, renal insufficiency, large stone burden residual stones.

Accessories and instrumentation

A 365 micron laser fiber is suited for ureteral stones. The 200 micron fiber preserves tip deflection. Holmium laser is the preferred energy source for flexible ureteroscopy. **Nitinol baskets preserve tip deflection**, in addition the tipless design reduces the mucosal injury, hence they are more suited for flexible ureteroscopy ⁽³⁰⁾

Access sheaths have been used by various workers. The size of the available access sheaths ranges from 9-16Fr, they have a hydrophilic coating. Generally they are introduced over a wire. The advantages of access sheath are reducing the operating time particularly in large stone burden. Another theoretical advantage is, it helps in maintaining a low pressure in the pelvicalyceal system ⁽³¹⁾

Recommendations:-

Flexible ureteroscopy offers a good treatment option for calculi less than 20mm in size. Flexible URS is not recommended as a first line of treatment for renal calculi. It has been demonstrated as a effective way of treating stones which are refractory to ESWL. Stenting after a uncomplicated ureteroscopy is optional. It is mandatory that sterile urine should be documented prior to intervention.

Staghorn calculi:-

A retrospective study with 200 patients has shown that renal deterioration occurs in 28% of patients with staghorn calculi treated conservatively. This emphasizes the fact that **staghorn stones should be aggressively managed surgically⁽³²⁾ PCNL should be the recommended modality as clearance rates are greater than 3 times that of ESWL⁽³³⁾**

The following are the treatment options in staghorn calculi:-

- 1) **Percutaneous nephrolithotomy** should be the **first treatment** utilized for most patients.
(level2)
- 2) **ESWL should not be used as the preferred treatment modality for staghorn stones.**
- 3) **Open surgery should be recommended only if the stones are not expected to be removed in a reasonable number of stages.**
- 4) **Nephrectomy should be considered in non functioning kidneys.** ⁽¹⁾

Recommendations:-

PCNL is the first choice for staghorn calculi. Open surgery is desirable in the situation when expertise is not available wherein the stone can be cleared in reasonable number of stages and tracts. Nephrectomy should be considered for non functioning kidneys.

Management of ureteric calculi and ureteric colic

The most common cause for ureteric colic is ureteric calculus. The priority in these patients should be relief of pain. The subsequent management of patients with ureteric colic would be determined by the level of obstruction and the stone size.

j) Agents recommended for relieving pain

It is recommended that pain should be relieved with diclofenac whenever possible. A alternative drug might be used if pain persists. Further more it has been shown that the resistive index significantly reduces if diclofenac is administered.. **Level 4 evidence suggests that hydromorphone might be helpful, however there is a significant risk of vomiting** ^{(34) (35) (36)}
Diclofenac can affect renal function in patients with already reduced function. There is however no effect if the kidneys are functioning normally⁽³⁷⁾

ii) Agents for preventing episodes of renal colic

Diclofenac sodium is recommended for the purpose. Studies indicate that the incidence of recurrent renal colic decreases with administration of diclofenac sodium. ⁽³⁸⁾ When the pain is unremitting the treating urologist should think of alternative measures such as drainage by stenting or percutaneous nephrostomy or even removal of the stone.

iii) Medical expulsive therapy (MET)

The beneficial effect of these drugs is attributed to ureteral smooth muscle relaxation mediated through inhibition of calcium channel pumps or alpha receptor blockade. The prerequisite for this approach is that the patient should be comfortable this approach. And there should not be any immediate indication for stone removal.. **Studies indicate that alpha blockers facilitate ureteral passage ,while nifedipine provides marginal benefit. Alpha blockers are recommended for MET**⁽²⁾

Ureteric calculi

Guidelines for Index patients

- Patients with bacteriuria should be treated with appropriate antibiotics
- Blind basketing without visualization endoscopically should not be performed.

- Patients with newly diagnosed stones less than 6 mm and well controlled symptoms, should be advised MET
- Patients who opt for Medical expulsion therapy should have well controlled pain, no evidence of sepsis, and adequate functional reserve, such patients should be periodically observed for stone position and assessment of hydronephrosis.
- Stone removal is recommended in persistent obstruction, failure of stone progression. or increasing or unremitting colic.
- Patient should be informed about the available treatment options.
- Both ESWL/ flexible URS are the preferred treatment options for upper ureteric calculi less than 1cm in size. For larger stones Antegrade ESWL/PCNL/laposcopic removal are recommended depending on expertise and instruments available
- URS is the preferred modality for distal and midureteric calculus.

Recommendations:-

Alpha blockers are recommended for MET. It is recommended that pain should be relieved with diclofenac whenever possible. Patients with newly diagnosed stones less than 6 mm and well controlled symptoms, should be advised MET .Patients who opt for Medical expulsion therapy should have well controlled pain, no evidence of sepsis, and adequate functional reserve, such patients should be periodically observed for stone position and assessment of hydronephrosis. Both ESWL/ flexible URS are the preferred treatment options for upper ureteric calculi less than 1cm in size. For larger stones antegrade ESWL/PCNL/laposcopic removal are recommended depending on clinical situation expertise and instruments available. URS is the preferred modality for distal and midureteric calculus

Treatment of calculi in special situations

Calyceal diverticular stones

Once symptomatic all these stones require treatment. **ESWL, PCNL, laparoscopy and observation remain the treatment options which can be offered to the patient.** As the drainage of the calyx in concern is at times questionable ESWL has rather poor results. Sometimes the combination this treatment modality is recommended⁽³⁹⁾.

Anomalous kidneys

These group of patients include those patients with stones in ectopic, horseshoe or kidneys with fusion anomalies. The approach to managing these stones should be individualized. The factors to be taken into consideration are the stone bulk, the location of the stone, the vascular and the anatomy of the pelvicalyceal system. Ultrasound helps in gaining access in ectopic kidney apart from being a diagnostic tool. **CT is pivotal in deciding the management and choosing the method of treatment in anomalous kidney..**

CT will also give the attenuation values and be a deciding factor in deciding ESWL or flexible ureteroscopy. Flexible ureteroscopy will be useful tool in stones small burden stones in size with the availability of smaller flexible ureteroscopes, and access sheaths. However the surgeon should consider complete “on table” clearance in these patients as the drainage is likely to be impaired. USG guided approach for ectopic kidneys should be done by surgeons well versed with it. Laparoscopic assisted PCNL has shown good clearance rates with minimal morbidity and less likely hood of ancillary procedures. Although adequate fragmentation can be achieved with ESWL, the drainage of fragments might be impaired due to the anatomical abnormalities. The choice of ESWL as a treatment option should be done prudently.⁽⁴⁰⁾

Pediatric urolithiasis

Although the treatment modalities used are same in children as in adults. Specific points should be noted in children. **The indications for ESWL are similar to those in adults. Stones in Children with a diameter of less than 20mm are ideal cases. The success rates decreases as stone burden increases. Larger stones should be treated with PCNL** ⁽²⁾.

They are as follows:-

- 1) Children have a tendency to pass larger fragments.
- 2) Ultrasound should be the modality for localization of stone when ESWL is the modality chosen.
- 3) Smaller instruments should be used for endourologic manipulations⁽²⁾

Role of open surgery in the current era

In a developing country such as India, the cost factor plays a major role, which is mostly borne by the patient or a health care delivery mechanism, A study from India by Sinha et al , which although is a retrospective data and has a small sample size suggests that PCNL is less costly and as effective as open surgery. However randomized level 1 evidence by Al Kohlany et al comparing open surgery with PCNL suggests that PCNL offers equivalent clearance as open pyelolithotomy, with less morbidity, short hospital stay, and less renal damage. **The trade off in a Indian clinical scenario will be to offer the best cost effective alternative available** ⁽⁴¹⁾⁽⁴²⁾⁽⁴³⁾

Nephrolithiasis –metabolic work up

See recommendation in section on- Nephrolithiasis –metabolic work up .

Who does what/ and timeline

Doctor

The treating doctor ideally should be an Urologist or a surgeon trained in Urology. He is responsible for the initial workup of the patient and subsequent management of the patient. He is responsible for counseling the patient regarding the success rates, complications and possible outcome of any given procedure. All possible treatment options in a given clinical situation should be discussed with the patient. The patient on discharge should be given instructions for follow up and measures (dietary and pharmacologic) to prevent stone recurrence.

Nursing and technical staff:-The nursing staff should be trained in the aspect of maintenance and use of endourologic equipment, considering the fragility and cost of these equipments. The responsibility of sterilization of these equipment lies with these personnel .The technical/nursing staff prepares the trolley and assists the surgeon during the procedure.

Referral criteria:-

The criterion for referral remains, lack of appropriate infrastructure and expertise at primary level.

The indications for referral to tertiary care centre in managing stones disease are:-

- 1)Complex calculi (multiple stones , staghorn calculi, stones with CKD, stones with obstructive uropathy) where in the opinion of the treating physician , the patient needs nephrolurological care and advanced surgical and medical care from a infrastructure standpoint
- 2) Special situations such as pediatric urolithiasis, stones in ectopic kidney.

Annexure 1

Indications and selection of modality for treating calculi in a index patient

It depends on the stone size location, stone composition and BMI of the patient

The following are the guidelines to be followed

- 1) Stone less than 1cm in the kidney -ESWL
- 2) Stone more than 1cm and less than 2cm in the kidney , -Flexi URS/ESWL/PCNL
- 3) Any stone more than 2cm in the kidney-PCNL
- 4) All staghorn and partial staghorn-PCNL
- 5) Non progressive more than 6mm stone in the mid and lower ureter-semirigid URS.
- 6) Stones less than 1cm in upper ureter-ESWL
- 7) stones larger than 1cm in upper ureter-PCNL/ESWL/Flexi URS

Further reading

- Preminger GM, Assimos DG, Lingeman JE et al Nephrolithiasis guideline panel chapter 1 AUA guideline on management of staghorn calculi : Diagnosis and treatment recommendation J Urol 2005;173:1991-2000.
- EAU guidelines on Urolithiasis Turk, T Knoll, A Petrik, K Sarica, C Seitz, M Straub, O Traxer 2010
- Worster A, Preyra I, Weaver B, Haines T The accuracy of non contrast helical computed tomography versus intravenous pyelography in the diagnosis of suspected acute urolithiasis A metanalysis Ann emerg Med 2002 ;40(3):280-6
- Morcos SK, Thomsen HS, Webb JA. Contrast media safety committee of the European society of urogenital radiology prevention of generalized reactions to contrast media ; A consensus report and guidelines Eur Radiol 2001;11(9):1720-8
- Thomsen HS, Morcos SK, Contrast media and the kidney: European society of urogenital radiology (ESUR) guidelines Br J Radiol 2003; 76(908):513-8.
- P Aga, R Bansal Is intravenous urogram no longer an imaging of choice for percutaneous nephrolithotomy Indian JUrol 2010;26:303-4.

- 7) Andersson L, Sylven M Small renal calyceal calculi as a cause of pain J Urol 1983; 130(4):752-3.
- 8) Coury TA, Sonda LP, Lingeman JE, Kahnoski RJ, Treatment of painful calyceal Stones urology 1988; 32(2); 119-23.
- 9) Hubner W, Porpaczy P Treatment of calyceal calculi Br J Urol 1990;66(91) :9-11
- 10) Brandt B, Ostri P, Lange P, Kristenssen J. Painful calyceal calculi. The treatment of small non obstructing calyceal calculi in patients with symptoms. Scand J urol Nephrol 1993;27(10):75-6.
- 11) Suleiman MN, Buchholz NP, Clark PB. The role of ureteral stent placement in the Prevention of steinstrasse J Endourol 1999;13(3):151-5.
- 12) Perale MS, Lingeman JE, Leveille R, Kuo R, Preminger GM, Nadler RB, Macaluso J, Monga M, Kumar U, Dushinski J, Albala DM, Wolf JS, Assimos D, Fabrizio M, Munch LC, Nakada SY, Auge B, Hoeny J, Ogan K, Pattaras J, McDougall EM, Averch TD, Turk T, Pietrow P, Watkins S Prospective Randomized trial comparing shock wave lithotripsy and ureteroscopy for lower pole calyceal calculi 1cm or less J urol 2005; 173(6);2005-9.
- 13) Shah K, Kurien A, Mishra S, Ganpule A, Muthu V, Sabnis RB, Desai M predicting effectiveness of extracorporeal shockwave lithotripsy by stone attenuation value Endourol 2010;24(7);1169-73
- 14) El Nahas AR, El Assmy AM, Manour O, Sheir KZ. A prospective multivariate analysis of factors predicting stone disintegration by extracorporeal shock wave lithotripsy: The value of high resolution non contrast computed tomography Eur Urol 2007; 51(6):1688-93.
- 15) Pishchalnikov YA, Neucks JS, VonDeHarr RJ, Pishchalnikova IV, Williams JS

- Jr, McAteer JA. Air pockets trapped during routine coupling in dry head lithotripsy can significantly decrease the delivery of shock wave energy. *J Urol* 2006; 176(6 pt 1):2706-10.
- 16) Neucks JS, Pishchalnikov YA, Zancanaro AJ, VonDer haar JN, Williams JC Jr, McAteer JA. Improved acoustic coupling for shock wave lithotripsy *Urol Res* 2008; 36(1):61-6.
- 17) Semins MJ, Trock BJ, Matalaga BR the effect of shock wave rate on the Outcome of shock wave lithotripsy: A metanalysis *J Urol* 2008 ;179(1):194-7.
- 18) Connors BA, Evan AP, Blomgren PM, handa RK, Willis LR, Gao S Effect of initial shock wave voltage on shock wave lithotripsy-induced lesion size during step wise voltage ramping *BJU Int* 2009;103(1):104-7.
- Mehrabi S, Karimzadeh Shiraji K).Results and complications of spinal anesthesia in percutaneous Nephrolithotomy *Urol J* 2010;7(1):22-5
- 20) Scoffone CM, cracco CM, Cossu M, Grande S, Poggio M, Scarpa RM Endoscopic combined intrarenal surgery in Gladakao –modified supine Valdivia position: A new standard for percutaneous nephrolithotomy? *Eur Urol* 2008;54(6):1393-403.
- 21) De Sio M, Autorino R, Quatro , Calabo F, Damiano R, Giuglioano F, Mordente, S, D'Armiento M Modified supine versus prone position in Percutaneous nephrolithomy for renal stones treatable with single percutaneous renal access. A prospective randomized trial *Eur Urol* 2008; 54(1):196-202.
- 22) Basiri A, Ziaee AM, Kianian HR, Mehrabi S, Karami H, Moghadam SM. ultrasonographic versus fluoroscopic access for percutaneous

- nephrolithotomy: A randomized clinical trial J Endourol 2008;22(2):281-4.
- 23) Desai M, Jain P, Ganpule A, Sabnis R, Patel S, Shrivastav P. Developments In technique and technology: Effect on the results of percutaneous nephrolithomy for staghorn calculi 2009;542-548.
- 24) Albala DM, Assimos DG, Clayman RV, Denstedt JD, Grasso M, Gueteriz AJ, Kahn RI, Leveillie RJ, Lingeman JE, Macaluso JN Jr, Munch LC, Nakada SY, Newman RC, Pearle MS, Preminger GM, Teichman J, Woods JR. Lower pole I A prospective randomized trial of extracorporeal shock wave lithotripsy and percutaneous nephrolithotomy for lower pole nephrolithiasis-initial results J Urol 2001;166(6):2072-80.
- 25) Desai MR, Kukreja RA, Desai MM, Mhaskar SS, wani KA, Patel SH, Bapat SD. A prospective randomized comparison of type of nephrostomy Drainage following percutaneous nephrolithotomy: large bore versus small bore versus tubeless J urol 2004;172(20):565-7
- 26) Agarwal MS, Agarwal M, Gupta A, bansal s, Yadav A, Goyal J. A randomized comparison of tubeless and standard percutaneous nephrolithotomy. J Endourol 2008; 22(3)439-42.
- 27) Knopf HJ, Graff HJ, Schulze H . Perioperative antibiotic prophylaxis in ureteroscopic stone removal Eur Urol 2003; 44(1):115-8.
- 28) Grabe M. Perioperative antibiotic prophylaxis in urology Curr Opin Urol 2001; 1191:81-5.
- 29) Michel MS, Knoll T, Ptaschnyk T, Kohrmann KU, Alken P. Flexible ureterorenoscopy for the treatment of lower pole calyx stones; influence of different lithotripsy probes and stone extraction tools on scope deflection

- and irrigation flow. Eur Urol 2002; 41(3):312-6.
- 30) Teichman JM, rao RD,rogenes VJ,harris JM. Ureteroscopic management Of ureteral calculi:Electrohydraulic versus holmium Yag lithotripsy J Urol 1997;158(4):1357-61.
 - 31) Rehman J, Monga M, landaman J, Lee DI, Felfela T, Conradie MC, srinivas R, Sundaram CP, Clayman RV, Characterisation of intarpelvic pressures during ureteropyeloscopy with ureteral access sheaths Urology 2003;61(4):713-8.
 - 32) Tiechman JM, long RD, Hulbert JC Long term renal fate and prognosis after staghorn calculus management J urol 153:1403, 1995) .
 - 33) Mertyk S, Gofrit ON, gafni O, Pode D, Shapiro A Verstandig A et al Complete staghorn calculi; randomized prospective comparison between extracorporeal shock wave lithotripsy monotherapy and combined with percutaneous nephrolithotomy J Urol 157:780, 1997.
 - 34) Lundatm So, wahlander LA, Kral LG Treatment of ureteric colic by prostaglandin synthetase inhibition with diclofenac sodium Curr Ther Res 1980;28::355-8.
 - 35) Walden M, lahtainen J, Elvander E Analgesic effect and tolerance of ketoprofen and diclofenac in acute ureteral colic Sacnd J Urol Nephrol 1993;27(3):323-5
 - 36) Shokeir A Abdulmaaboud M, Farage Y, Mutabagani H Resistive index in renal colic :The effect of non steroidal anti-inflammatory drugs BJUI Int 1999;84(3):249-51.
 - 37) Lee A, Cooper MG, Craig JC, Knight JF, Keneally JP Effects of non

steroidal anti inflammatory drugs on post operative renal function in adults with normal renal function Cochrane Database Syst Rev 2007,18(2):CD002765)

- 38) Laerum E, Ommudsen OE, Gronseth JE, Chrsiationasen A, fagertun HE. oral diclofenac in prophylactic treatment of recurrent renal colic. A double blind comparison with placebo Eur Urol 1995; 28(2):108-11.
- 39) Gross AJ, Hermann TR. Management of stones in calyceal diverticulum. Curr opin urol 2007;17(2):136-40.
- 40) Ganpule AP, Desai MR Urolithiasis in kidneys with abnormal lie, rotation or form Curr Opin Urol 2011;21(2):145-53.
- M Sinha et al A cost comparison of open versus percutaneous approaches to the management of large staghorn calculi Indian J Urol 2008;24:28-34
 - Goel MC et al Management of staghorn calculi : analysis of combination therapy and open surgery Urol Int 1999;63:228-33
 - Al Kohlany et al Treatment of complete staghorn stones: A prospective randomized Comparison of open surgery versus percutaneous nephrolithotomy J urol 2005;175:469-73

Annexure 1

Resources required for one patient/procedure (units)

Human resources

ESWL

- i. Urologist-1
- j. Technician-1

k. Anesthetist-1

PCNL

12. Urologist-1

13. Surgical assistant-1

14. Technician/Nurse-2

15. Anesthetist-1

Flexible ureteroscopy

1) Urologist-1

a) Surgical assistant-1

3) Technician/Nurse-2

4) Anesthetist-1

Investigations:- As detailed in previous section

Drugs and consumables

List of consumables for PCNL

Normal saline 1000ml-(n=4)

5% Dextrose 1000ml-(n=2)

Normal saline -3000ml-(n=3)

Iv set – (n=1)

Injection Fortwin – (n=1)

Injection Metoclopramide-(n=4)

Injection Tramadol 50 mg –(n=4)

Injection ranitidine-50 mg-(n=4)

Foley catheter 16 fr-(n=1)

Urobag-(n=2)

Irrigation set-(n=1)

Phosphate enema-(n=1)

Injection glycopyllotrate-(n=1)

Antibiotic according to clinical situation

List of consumables for ureteroscopy

Normal saline 1000ml-(n=4)

5% Dextrose 1000ml-(n=4)

Normal saline -3000ml-(n=3)

Iv set – (n=1)

Injection Fortwin – (n=1)

Injection Metoclopramide-(n=4)

Injection Tramadol 50 mg –(n=4)

Injection ranitidine-50 mg-(n=4)

Foley cathter 16 fr-(n=1)

Urobag-(n=1)

Irrigation set-(n=1)

Phosphate enema-(n=1)

Injection glycopyllotrate-(n=1)

Antibiotic according to clinical situation

Equipment

Trolley preparation for PCNL

Tray with cover-2

Legging-2

Towel clips-5

Towel -2

Surgeon gown -3

Gloves -3

Hole towel-2

Artery forcep-2

Needle holder-1

Number 11 knife-1

Sponge holder -1

Scissor-1

Knife holder-1

Thread-1

20cc syringe-2

10 cc syringe-1

Bowl-1

Xylocaine jelly-2

Cystoscope sheath (19 Fr/20 Fr)

Telescope-30 degree

Light cable with cord 1 in number

Open end ureteric catheter-1 in number
Nephroscope -24-26 Fr (depending on availability)
Suction pipe-1
Stone holding forcep-1
Spanner -1
Ultrasound probe (optional)
Puncture needle-1
Metal rod/Telescopic metal dilators (till 24 Fr)-1
J tip guide wire/ glidewire-1
Teflon dilator with Upto 14 Fr-1
Amplatz dilator set-1
Amplatz sheath (size depends on surgeon preference)
Nephrostomy catheter (Nelaton preferable)

Trolley preparation for URS

Trolley with cover-1
Legging-2
Hole towel-1
Gown with napkin-1
Gloves-3
Towel clip-2
Sponge holder-1
Bowl-1
Scissors-1

Ureteric catheter-1

Ureteric dilator set-1

Irrigation tube-1

Cystoscope sheath with bridge-1

Telescope-30 degree-1

Guide wire 0.035/glide wire-1 each

Ureteroscope (depends on surgeon preference)-1

Benign Hyperplasia Of Prostate (BPH)

Prof. Nitin S. Kekre, Professor and Head
Dr. Arabind Panda, Associate Professor
Department of Urology
CMC Medical College, Vellore

General comments:

Clinical guideline are supposed to be reflections of the best currently available evidence. They have 2 parts –

- a. A systematic review of the best available evidence and the strength of that evidence.
 - I. The methodology of systematic review is important. This should be clearly stated. All relevant studies should be studied. If Indian studies are available, then they should be included. The evidence should then be ranked using a standard system e.g. levels of evidence - Oxford Centre for Evidence-based Medicine [1]. If necessary relevant focused questions can be framed in order to exactly define the purview of the exercise.
- b. Recommendations for practice based on that evidence. These should be graded according to the level of available evidence.

This standard treatment guideline on BPH does not state the methodology used to arrive at the recommendations. The levels of evidence are not mentioned. There is no grading of the recommendations. The document is without any references to back up the claims. The authors should be clearly mentioned in the published version (we understand this is not desirable in a document for peer review). A conflict of interest declarations should be included in the final document.

Use of the term benign hyperplasia of the prostate (BPH) – BPH is a histological diagnosis. Its symptoms come under the umbrella of lower urinary tract symptoms. While BPH occurs in the vast majority of elderly men, it can be difficult or impossible to directly attribute the symptoms of the patient to BPH.

Introduction

Line 17 – 20 : ”However, a significant proportion, particularly in rural areas tend to disregard symptoms till complications develop and this segment requires a more proactive and individualized approach.” – There is no evidence that the rural population disregard symptoms more than the urban people. The lack of access to effective health care in rural areas will make a proactive and individualized approach difficult. It is important for guidelines to be applicable to the entire populations of the country.

Evaluation of BPH

1. Symptom assessment – Need to state the complete term International Prostatic Symptom Score before using the abbreviation IPSS.

Mandatory diagnostic tests

2. PSA measurement – Need to state the complete term. There is no evidence that prostate specific antigen measurement has any role in the routine management

- of BPH. The role of PSA screening for prostate cancer is controversial. Metaanalysis of the recent evidence showed screening to have no significant impact on either overall mortality or death from prostate cancer with significant overdiagnosis and overtreatment and is unlikely to save lives. It cannot be recommended in India. A patient anxious about prostate cancer should be explained about the benefits and risks of PSA screening and about the available evidence. He should be then in a position to make an informed choice.
3. Abdominal ultrasound evaluation –Upper tract imaging is not required for routine evaluation of BPH. The estimation of prostate size by abdominal ultrasound is also unreliable. Ultrasound evaluation should be restricted to the bladder and post void residual urine as an optional test.
 4. Uroflowmetry – This is not mandatory even in developed countries. The equipment is specialized, expensive (Indian makes cost Rs. 50000/- approx., foreign equipment – 1.5 – 2.5 lacs/ - approx.) and require regular maintenance and calibration. It cannot be mandatory and should be an optional test.

Optional diagnostic tests

2. Blood urea – Blood urea estimation is superfluous when creatinine is being measured. It is not as accurate indicator of renal function as creatinine. Unnecessary.
 3. Urine Cytology – Urinary cytology is a specialized test with low sensitivity. In absence of microscopic haematuria, it is unlikely to be useful.
 6. Urethrography – An uroflowmetry is a non invasive test which can indicate a possible urethral stricture. An urethrography is invasive and will require prior urine culture sensitivity before its performance.
- Uroflowmetry and ultrasound abdomen can be added as optional tests.

Treatment options

2. a. “Dose titration is not essential for Alfuzosin and Tamsulosin ” should read - Dose titration is not required for extended release Alfuzosin and Tamsulosin.
“Hypotensive episodes are least seen with use of Alfuzosin” – The vasodilatory effects of Alfuzosin and Tamsulosin are similar. There are no statistical differences between the two in this regard [4].
 - b. 5 Alpha reductase inhibitors:** “Reduction of blood loss during TURP is evident only after long term use of 5 ARI’s.” - The evidence is very weak and not enough for a recommendation[5,6,7,8].
 - c. Combination therapy:** “Concomitant use of Alpha adrenergic blockers and 5Alpha reductase inhibitors is appropriate therapy for patients with LUTS due to BPH, particularly if response has been insufficient with either drug.” - Combination

therapy is necessary in those who are at risk of progression (moderate to severe LUTS, enlarged prostates, and reduced Qmax) . Response is not a criterion for combination therapy [9].

3. Indications for surgery

“Patients presenting with chronic low pressure require catheterization and urodynamic evaluation” – Catheterization is not required unless the patient has acute or chronic retention, overflow incontinence or obstructive uropathy with raised creatinine.

4. Minimally invasive procedures

TUNA and intraprostatic stents – Cannot be recommended based on current evidence.

5. Surgical (endoscopic and open) procedures

- “Open prostatectomy is still an acceptable procedure for glands exceeding 100 gms in wt.” – Any gland over 60 gms can be managed with open prostatectomy if TURP is not available.

- f) “Follow-up with IPSS, DRE & PSA recommended every 3 to 6 months initially and annually thereafter.” – Three monthly follow up is not required after surgery. PSA is certainly not needed.

Conclusions: Very poorly written clinical practice guideline. It is unfit for use in its present form. Needs extensive revision.

References:

- Center for evidence based medicine, Oxford, UK <http://www.cebm.net/index.aspx?o=1025>. Accessed on 1st April, 2012.
- Ilic D, O'Connor D, Green S, Wilt TJ. Screening for prostate cancer: an updated Cochrane systematic review. *BJU Int*. 2011 Mar;107(6):882-91.
- Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. *BMJ*. 2010; 341:c4543
- Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of α -adrenergic blockers for symptoms related to benign prostatic hyperplasia. *Int J Clin Pract* 2008 Oct;62(10):1547-59.
- Hahn R, Fagerstrom T, Tammela T et al: Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. *BJU Int* 2007; 99: 587.

- Boccon-Gibod L, Valton M, Ibrahim H et al: Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostate. *Prog Urol* 2005; 15: 1085.
- Sandfeldt L, Bailey D, Hahn R: Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. *Urology* 2001; **58**: 972.
- Donohue J, Sharma H, Abraham R et al: Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. *J Urol* 2002; 168: 2024.
- Desgrandchamps F. Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS. *Curr Opin Urol* 14:17–20.

RENAL CELL CARCINOMA (RCC)

Renal cell carcinoma (RCC), which accounts for 2% to 3% of all adult malignant neoplasms, is the most lethal of the urologic cancers. The mortality rate of RCC is as much as twice that of bladder cancer^{1,2}. There is no epidemiological data available from Indian subcontinent. However, the disease is fairly prevalent in our country.

In 2010, an estimated 58,240 Americans were diagnosed with renal malignancies and 13,040 deaths were estimated³. In 2008, there were an estimated 88,400 new cases and 39,300 kidney cancer-related deaths from RCC in Europe⁴.

Surgical excision remains the only curative treatment as this tumor is remarkably resistant to radiotherapy and chemotherapy.

Presentation –

- **Incidental:** detected on imaging (CT / ultrasound) performed for other indication
- **Symptomatic:** local / metastatic / paraneoplastic
 - Flank pain, hematuria, mass
 - Weight loss, fever, night sweats, recent onset hypertension, anemia / polycythemia
 - Cervical lymphadenopathy / non-reducing varicocele / pathological fracture
 - others

Workup –

Any mass lesion detected on ultrasound needs further imaging.

- b) **CT / MRI abdomen & pelvis/ MR Urography** – both without and with contrast (if renal functions permissible). MRI specifically indicated if disease is infiltrating adjacent organs or IVC thrombus (triphasic multiplanar CT or high resolution color Doppler ultrasound optional for the latter).

- c) **Blood investigations** – Hemogram, kidney functions, alkaline phosphatase (ALP), calcium, albumin, lactate dehydrogenase (LDH)
- d) **Chest X-ray** – in all cases. Further imaging (CT scan) required only if clinically indicated or primary tumor locally advanced or lymph-nodes enlarged
- e) **Bone scan** – only if clinically indicated (bone pain, raised ALP) or primary tumor locally advanced or lymph-nodes enlarged.
- f) **PET CT** – not routinely recommended in the workup for RCC. Has good specificity but low sensitivity in the evaluation of metastatic disease. Currently, it may be considered in case of equivocal findings on conventional imaging, where detection of metastatic disease will influence management decision.
- g) **Biopsy / FNAC** – not required in most cases. Acceptable in the following indications:
 - h) Considering inflammatory mass / lymphoma / metastasis, vague Radiology, multiple masses, associated significant lymphadenopathy
 - i) Considering non-surgical therapy (e.g. cryotherapy, systemic therapy in case of metastatic disease) / active surveillance (small renal masses) / watchful waiting

Staging (American Joint Committee on Cancer, TNM staging system for renal cancer, 7th ed, 2010) –

| Primary tumor | |
|----------------------|--|
| Tx | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| T1a | Tumor dia ≤ 4 cm confined to kidney |
| T1b | Tumor dia > 4-7cm confined to kidney |
| T2a | Tumor dia > 7-≤10cm confined to kidney |
| T2b | Tumor dia > 10cm confined to kidney |

| | |
|-----------------------------|--|
| T3a | Tumor grossly extends into renal vein or its muscle-containing branches; tumor invading perirenal or sinus fat |
| T3b | Tumor grossly extends into vena cava below diaphragm |
| T3c | Tumor grossly extends into vena cava above diaphragm or invades its wall |
| T4 | Tumor invades beyond Gerota's fascia (including contiguous spread into ipsilateral adrenal) |
| Regional lymph nodes | |
| Nx | Regional lymph nodes cannot be assessed |
| N0 | No regional lymph node metastasis |
| N1 | Metastasis in single regional lymph node (s) |
| Distant metastasis | |
| M0 | No distant metastasis |
| M1 | Distant metastasis |

| | | | |
|-----------------------|-------|-------|----|
| Stage Grouping | | | |
| Stage I | T1 | N0 | M0 |
| Stage II | T2 | N0 | M0 |
| Stage III | T1-2 | N1 | M0 |
| | T3 | N0-1 | M0 |
| Stage IV | T4 | Any N | M0 |
| | Any T | Any N | M1 |

Stage wise treatment –

In addition to clinical stage, patient's performance status (ECOG⁵) should be taken into consideration before deciding the treatment options.

Stage I

Preferred – nephron-sparing surgery if technically feasible

Optional – radical nephrectomy*

Others

9. Active surveillance

10. Ablative therapies (cryotherapy, radiofrequency ablation, microwave thermotherapy, high frequency focussed ultrasound, etc.)

Adrenalectomy / lymphadenectomy: not indicated, unless grossly involved intraoperatively (staging changed)

** In patients with early stage RCC radical nephrectomy is justified when NSS is technically not feasible / the patient understands the other option (NSS) and opts for RN.*

Stage II

Preferred – radical nephrectomy

Optional (imperative setting**) – nephron-sparing surgery

Adrenalectomy / lymphadenectomy: not indicated

*** Imperative indications of NSS: solitary kidney, compromised function or reserve of contralateral kidney (chronic renal insufficiency, severe diabetes mellitus, severe hypertension), bilateral synchronous tumors, familial RCC*

Stage III

Preferred – radical nephrectomy, with tumor thrombectomy (if present)

Lymphadenectomy – may be performed for better staging. LND in patients with high-risk disease improves stage assessment and may prolong survival^{6,7}. A mere sampling of the renal hilar lymph nodes is insufficient for pathologic staging. For right sided tumor, paracaval and interaortocaval lymph nodes and for left sided tumor para-aortic and interaortocaval lymph nodes should be removed from the crus of the diaphragm to the common iliac artery. If disease is confirmed within the interaortocaval nodes, a complete retroperitoneal LND is recommended to define the full extent of metastatic lymph node involvement⁸.

Adrenalectomy: not required unless direct invasion or tumor nodule (stage changed)

Stage IV

16. Nephrectomy with adjacent organ excision

17. Metastasectomy (if solitary metastasis)

18. Adrenalectomy

19. Cyto-reductive nephrectomy

Patients of stage IV disease are candidates for adjuvant systemic therapy (*vide infra*).

Socio-economic and facility issues –

Advanced –

- staging tools
- surgical facility
- follow up facility
- socio-economic support

may not be available everywhere.

Centers which intend to treat RCC must be equipped with facility for histopathology / CECT / Blood transfusion.

If above facilities not available / locally advanced disease / patient wants NSS → ref. to higher center.

Follow up protocol after definitive local treatment –

Risk grouping (UCLA integrated staging system)⁹:

| | | | | | | | | | | | | | |
|----------------------|-----|-----|--------------|-----|-----|-----|-----|---|-----|-----|------|-----|--|
| T stage | 1 | | | | 2 | | 3 | | | | 4 | | |
| Furhman grade | 1-2 | | | 3-4 | | 1-4 | | 1 | | 2-4 | | 1-4 | |
| ECOG PS | 0 | ≥ 1 | | | Any | ≥ 1 | Any | 0 | ≥ 1 | 0 | ≥ 1 | Any | |
| Risk group | Low | | Intermediate | | | | | | | | high | | |

Follow up protocol based on the above risk grouping¹⁰ –

| | | 6m | 12m | 18m | 24m | 30m | 36m | 42m | 48m | 54m | 60m | 6y | 7y | 8y | 9y | 10y |
|------------|---|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|----|----|----|-----|
| Hx/Ex/labs | L | - | √ | - | √ | - | √ | - | √ | - | √ | - | - | - | - | - |
| | I | √ | √ | √ | √ | √ | √ | - | √ | - | √ | √ | √ | √ | √ | √ |
| | H | √ | √ | √ | √ | √ | √ | - | √ | - | √ | √ | √ | √ | √ | √ |

| | | | | | | | | | | | | | | | | |
|------------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CT chest* | L | - | √ | - | √ | - | √ | - | √ | - | √ | - | - | - | - | - |
| | I | √ | √ | √ | √ | √ | √ | - | √ | - | √ | √ | √ | √ | √ | √ |
| | H | √ | √ | √ | √ | √ | √ | - | √ | - | √ | √ | √ | √ | √ | √ |
| CT abdomen | L | - | - | - | √ | - | - | - | √ | - | - | - | - | - | - | - |
| | I | - | √ | - | √ | - | - | - | √ | - | - | √ | | √ | | √ |
| | H | √ | √ | √ | √ | - | √ | - | √ | - | √ | √ | | √ | | √ |

* CT chest can be replaced with CxR after initial 3 years.

L – low risk; I – intermediate risk; H – high risk group.

Systemic therapy –

Indications:

- l. Metastatic RCC with resectable disease (cytoreductive nephrectomy and metastatectomy should be done whenever feasible)
- m. Non-resectable Locally advanced / metastatic RCC

Agents–

| | |
|---|---------------------|
| | Name |
| • | Sunitinib |
| • | Sorafenib |
| • | Pazopanib |
| • | Bevacizumab + IFN-α |
| • | Tamsirolimus |
| • | Everolimus |
| • | IFN-α |
| • | High dose IL-2 |

Targeted therapy in the form of tyrosine kinase inhibitors (1-4) and m-TOR inhibitors (5-6) have become first line systemic treatment for management of metastatic RCC. A substantial improvement in progression-free survival and overall survival has been

achieved in large randomized controlled trials, when compared to Interferon- α . These agents have also been found to be effective in non-clear cell RCC, which are typically resistant to cytokines and interferons. Sarcomatoid variant is associated with poor prognosis, and a modest response with doxorubicin & gemcitabine is observed.

Limitations –

- high cost and limited availability
- significant side-effects
- efficacy

Note : Targetted therapy for metastatic RCC/ locally advanced RCC should be decided by Urologist and given in supervision of a Urologist.

References:

- Landis et al., 1999. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics: 1999. *CA Cancer J Clin* 1999; 49:8-31.
- Pantuck et al., 2001b. Pantuck AJ, Zisman A, Belldegrun AS: The changing natural history of renal cell carcinoma. *J Urol* 2001; 166:1611-1623.
- Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics 2010. *CA Can J Clin* 2010; 60: 277-300.
- Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. *Eur J Cancer* 2010; 46: 765–81.
- Oken MM, Creech RH, Tormey DC et al. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982; 5: 649-655.
- Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. *J Urol* 2003; 169: 2076–83.
- Vasselli JR, Yang JC, Linehan WM, et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. *J Urol* 2001; 166: 68–72.
- Crispel PL, Breau RH, Allmer C, et al. Lymph Node Dissection at the Time of Radical Nephrectomy for High-Risk Clear Cell Renal Cell Carcinoma: Indications and Recommendations for Surgical Templates. *Eur Urol* 2011; 59: 18-23.
- Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. *J Clin Oncol*. 2002; 20: 4559-4566.
- Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. *Rev Urol* 2006; 8: 1-7.

BLADDER CANCER

I. WHEN TO SUSPECT / RECOGNIZE?

a) Introduction / b) Case definition: Bladder carcinoma is the most common malignancy of the urinary tract and is the 9th most common cancer diagnosis worldwide. At the initial diagnosis of bladder cancer, 70% of cases are diagnosed as non-muscle-invasive bladder cancer (NMIBC) and approximately 30% as muscle-invasive disease. [1, 2]

Non-muscle-invasive bladder cancer: Bladder cancer that does not involve the muscularis propria.

Invasive bladder cancer: Bladder cancer that histologically invades the muscularis propria.

- Risk factors [3,4,5,6]
 - Tobacco consumption
 - Occupational exposure to chemicals
 - Radiation therapy
 - Chronic urinary tract infection
 - Bladder schistosomiasis
 - Chemotherapy – Cyclophosphamide
- Active and passive tobacco smoking continues to be the main risk factor, while exposure-related incidence is decreasing.

II. INCIDENCE OF THE CONDITION IN OUR COUNTRY: Exact incidence is unknown. The recent trends indicate increasing incidence of bladder cancer. This may be partially attributed due to better detection and improved health care. Expected to be of same incidence as the western world.

III DIFFERENTIAL DIAGNOSIS:

20. Chronic cystitis
21. Tuberculous cystitis
22. Bladder calculi
23. Interstitial cystitis
24. Radiation cystitis
25. Eosinophilic cystitis

IV. PREVENTION AND COUNSELING:

11. Mass education about bladder cancer and its relationship with tobacco use
12. Anti-tobacco campaign
13. Careful history about smoking, occupational exposure to risk factors and storage LUTS
14. Detailed evaluation of all patients with gross hematuria and elderly patients (>40 years) with microscopic hematuria and associated risk factors like smoking
- 15. All patients with hematuria should undergo full urological evaluation**

16. Prompt referral of men with advanced bladder cancer to higher centers for further evaluation

V. OPTIMAL DIAGNOSTIC CRITERIA, INVESTIGATIONS, TREATMENT & REFERRAL CRITERIA

Diagnostic criteria:

1. History of gross painless hematuria
2. History of severe storage LUTS – may be due to CIS
3. Recurrent cystitis in elderly
4. Positive cytology
5. Cystoscopic examination and imaging studies showing tumour(s) in the bladder.

Diagnosis –The diagnosis mainly depends on the cystoscopic examination of the bladder, biopsy, and urine cytology. The initial therapy for bladder tumours is complete macroscopic transurethral resection of bladder tumours (TURBT) including a part of underlying muscle [7]. Cold cup biopsies should be discouraged.

A second TURBT should be considered [8]:

1. If there is suspicion that the initial resection was incomplete
2. When multiple or large tumours are present
3. When pathologist reported no muscle in the specimen
4. When a high grade tumour (pT1G3) was detected.

The management algorithm is based on the diagnosis of invasion of muscularis propria or not.

Routine bladder mapping biopsies are not indicated except in

1. Patients with positive urine cytology with normal looking mucosa in cystoscopy
2. Biopsy of the apical prostatic urethra when there is a bladder neck tumour or when abnormalities of prostatic urethra are visible.

Carcinoma in situ (CIS) is diagnosed based on the histology of bladder mucosal biopsies. Fluorescent cystoscopy is recommended in these cases [9].

Investigations:

4. Urine cytology: Cytology is useful when a high-grade malignancy or CIS is present. It is used to predict high grade tumour before TUR. However, urinary cytology often is negative in the presence of low-grade cancer.
5. Ultrasonography (USG): Transabdominal USG permits characterization of renal masses, detection of hydronephrosis and visualization of intraluminal masses in the bladder. It can be as accurate as IVU for diagnosis of upper urinary tract obstruction [10]. The USG is thus a useful tool for investigation in patients with haematuria to detect obstruction; it cannot however exclude the presence of upper tract tumours.

6. Pelvic examination (Bimanual examination) under anaesthesia: Helpful in assessment of local staging in muscle invasive bladder cancer and advanced cases. Not of much value in superficial bladder cancers. Should be done along with TURBT.[11]
7. Cystoscopy & TURBT: Cystoscopy should describe all macroscopic features of the tumour (site, size, number and appearance) and mucosal abnormalities. A bladder diagram is recommended. The gold standard in establishing the diagnosis of bladder tumour is TURBT.
8. Intravenous Urography (IVU): Intravenous urography (IVU) is used to detect filling defects in the calyces, renal pelvis and ureters, and hydronephrosis. Acceptable for staging of muscle invasive bladder cancer when CT Urography is not readily available [12].
9. CT Urography (CTU): CTU is mainly recommended for histologically proven muscle invasive bladder cancers for staging. It is not useful for making a diagnosis of muscle invasive bladder cancer. Pre TURBT CTU is indicated in select group of patients in whom it would significantly alter the management. Especially in muscle invasive tumours of the bladder and in upper tract tumours, CT urography gives more information than IVU does (including status of lymph nodes and neighbouring organs) [12].
10. MRI – abdomen and pelvis/ MR Urography: Optimal investigation for staging in muscle invasive bladder cancer Recommended only when there is definite contraindication for CT urography or IVU like contrast allergy and renal failure.
11. Serum alkaline phosphatase – if elevated indicates metastatic bone disease.
12. Bone scan –Indicated in patients with raised alkaline phosphatase and with bone pain.
13. CT scan of chest is recommended for optimal staging in muscle invasive bladder cancer; if not available chest X-ray is acceptable.

Staging of bladder cancer:

Based on Tumour Node Metastasis (TNM) classification of carcinoma bladder (2010) [13].

- **T - primary tumour**
- TX Primary tumour cannot be assessed
- T0 No evidence of primary tumour
- Ta Non-invasive papillary carcinoma
- Tis Carcinoma in situ. 'flat tumour'
- T1 Tumour invades subepithelial connective tissue
- T2 Tumour invades muscle
 - T2a Tumour invades superficial muscle (inner half)
 - T2b Tumour invades deep muscle (outer half)
- T3 Tumour invades perivesical tissue
 - T3a Macroscopically
 - T3b Microscopically (extravesical mass)

- T4 Tumour invades any of the following: Prostate, uterus, vagina, pelvic wall, abdominal wall
 - T4a Tumour invades prostate, uterus or vagina
 - T4b Tumour invades pelvic wall or abdominal wall
- **N - regional lymph nodes**
- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis
- N1 Metastasis in a single lymph node in the true pelvis (hypogastric, obturator, external iliac or presacral)
- N2 Metastasis in a multiple lymph nodes in the true pelvis (hypogastric, obturator, external iliac or presacral)
- N3 Metastasis in a common iliac lymph node(s)
- **M - distant metastasis**
- MX Distant metastasis cannot be assessed
- M0 No distant metastasis
- M1 Distant metastasis

Characteristics of Stages Ta, T1, and Tis

Stage Ta tumours are confined to the urothelium, have a papillary configuration of their exophytic part, and do not penetrate from the urothelium into the lamina propria or detrusor muscle.

Stage T1 tumours originate from the urothelium but penetrate the basement membrane which separates the urothelium from the deeper layers. T1 tumours invade into the lamina propria, but are not so deep that they reach the detrusor muscle.

Carcinoma in situ (Tis) is a high-grade (anaplastic) carcinoma confined to the urothelium, but with a flat non-papillary configuration. Unlike a papillary tumour, Tis appears as reddened and velvety mucosa and is slightly elevated but sometimes not visible. Tis can be local or diffuse.

Three types of Tis are distinguishable;

- Primary Tis (no previous or concurrent papillary tumours);
- Secondary Tis (with a history of papillary tumours);
- Concurrent Tis (in the presence of papillary tumours).

Characteristics of grade [14]:

1973 WHO Classification

Apart from their architecture, the individual cells show different degrees of anaplasia:

Grade 1: well differentiated tumour

Grade 2: moderately differentiated tumour

Grade 3: poorly differentiated tumour

2004 WHO Classification

A new classification system was initially proposed by the WHO/ISUP in 1998 and updated by the WHO in 2004. For non-invasive urothelial neoplasias, the categories are:

- **Flat lesions**
- Hyperplasia (flat lesion without atypia or papillary)

- Reactive atypia (flat lesion with atypia)
- Atypia of unknown significance
- Urothelial dysplasia
- Urothelial carcinoma *in situ* (CIS)
- **Papillary lesions**
- Urothelial papilloma (a completely benign lesion)
- Papillary urothelial neoplasm of low malignant potential (PUNLMP)
- Low-grade papillary urothelial carcinoma
- High-grade papillary urothelial carcinoma

The 2004 WHO grading system defines Tis as a non-papillary, i.e. a flat, lesion in which the surface epithelium contains cells that are cytologically malignant. Papillary tumours are classified as either papillary urothelial neoplasms of low malignant potential (PUNLMP) or as urothelial carcinomas, with the latter being subdivided into two grades: low grade and high grade. The intermediate group (G2) has been eliminated; this group was the subject of controversy in the 1973 WHO classification. Use of the 2004 WHO classification is advocated, as this should result in less diagnostic variability among pathologists.

Predicting recurrence and progression of tumours [15,16]:

TaT1 tumours

The pattern of recurrence and progression depends on the following clinical and pathological factors:

1. Number of tumours
2. Tumour size
3. Prior recurrence rate
4. T-category
5. Presence of concurrent CIS
6. Tumour grade.

CIS

No prognostic factors are well established. Retrospective studies suggest the following:

1. Concurrent CIS with T1 tumours have worse prognosis than primary CIS and secondary CIS [17, 18]
2. Responders to BCG have better prognosis than those non-responders. [19]

Treatment: Treatment strategy varies according to the stage and grade of bladder cancer.

Non-muscle invasive bladder cancer (superficial bladder cancer) NMIBC:

The standard initial therapy for Ta and T1 papillary bladder tumours is complete TURBT. Tumours less than 1cm in size can be resected enbloc. Larger tumours should be resected in fractions, which include the exophytic part, the underlying bladder wall and the edges of resection area. Complete and correct TUR is essential to achieve a good prognosis [20].

Prognostic Factors and Adjuvant Treatment

TaT1 papillary tumours

Recommendations for Low Risk Tumours

Patients with a single, small, low grade Ta tumour without CIS, who are at low risk for both recurrence and progression, should receive:

1. A complete TUR.
2. An immediate single post-operative instillation with a chemotherapeutic agent (drug optional – Mitomycin C preferred). [21]
3. No further treatment is recommended prior to recurrence.

Recommendations for High Risk Tumours

Patients with TaT1 high grade tumours with or without CIS and those with CIS alone are at high risk of progression. Treatment should consist of:

1. Complete TUR of papillary tumours followed by an immediate post-operative instillation with a chemotherapeutic agent (drug optional – Mitomycin C preferred).[21]
2. A second TUR after 4–6 weeks.[9]
3. Adjuvant intravesical immunotherapy with BCG (full dose or reduced dose in case of side effects). Maintenance therapy for at least 1 year (monthly once) is necessary [22,23] although the optimal maintenance scheme has not yet been determined.
4. Immediate cystectomy may be offered to patients at highest risk of tumour of progression (Patients with multiple tumours, large tumours (> 3 cm), and highly recurrent tumours (> 1 recurrence/year), stage T1 tumours with high grade tumours, and CIS).
5. In patients with BCG failure, cystectomy is recommended. [24]

Recommendations for Intermediate Risk Tumours

In the remaining intermediate risk patients, adjuvant intravesical therapy is necessary but no consensus exists regarding the optimal drug and the most appropriate scheme. BCG is more effective than chemotherapy in both reducing recurrence and progression. The major issue in the management of intermediate risk tumours is to prevent recurrence and progression, of which recurrence is clinically the most frequent. Treatment should include:

1. Complete TUR followed by an immediate postoperative instillation with a chemotherapeutic agent (drug optional).
2. A second TUR after 4–6 weeks when the initial resection was incomplete.
- 3i. Adjuvant intravesical chemotherapy (drug optional), schedule: optional although the duration of treatment should not exceed 1 year. **(Or)**
- 3ii. Adjuvant intravesical immunotherapy with BCG (full dose or reduced dose in case of side effects). Maintenance therapy for at least 1 year (monthly once) is necessary although the optimal maintenance schedule has not yet been determined.

Carcinoma *in situ*

CIS have a high risk of progression to muscle invasive disease which exceeds 50% in some studies. BCG intravesical immunotherapy (induction and maintenance) is superior to intravesical chemotherapy in increasing the complete response rate and the overall percent of patients remaining tumour free. Moreover, BCG reduces the risk of

progression as compared to either intravesical chemotherapy or a different immunotherapy [25]. Early radical cystectomy at the time of diagnosis provides excellent disease-free survival, but over-treatment occurs in up to 50% of patients.

Recommendations for the treatment of CIS

1. In concurrent CIS, the initial strategy (TUR, early intravesical instillation, a second TUR) is based on the features of the papillary tumour.
2. Intravesical BCG immunotherapy including at least 1 year maintenance.
3. After the 6 week induction course, a second course of 6 weekly BCG instillations or maintenance cycles consisting of 3 weekly instillations may be considered in non-responders since about 40-60% of these patients will respond to additional treatment with BCG. [23]
4. In BCG non-responders at 6 months, radical cystectomy is recommended. [26].

Muscle invasive bladder cancer:

Neo-adjuvant chemotherapy:

Neo-adjuvant cisplatin-containing combination chemotherapy improves overall survival by 5-7% at 5 years [27]. It should be considered irrespective of the type of definitive treatment. Neo-adjuvant chemotherapy is not recommended in patients with performance status (PS) > 2 and impaired renal function [28].

Radical Surgery and Urinary Diversion

Cystectomy is the preferred curative treatment for localized muscle invasive bladder cancer [29].

Radical cystectomy includes removal of regional lymph nodes, the extent of which has not been sufficiently defined [30]. A delay in cystectomy increases the risk of progression and cancer-specific death [31]. No pre-operative radiotherapy should be administered. Radical cystectomy in both sexes must not include the removal of the entire urethra in all cases, which may then serve as outlet for an orthotopic bladder substitution. If no bladder substitution is attached, the urethra must be checked regularly. Terminal ileum and colon are the intestinal segments of choice for urinary diversion. The type of urinary diversion does not affect oncological outcome.

Contraindications for orthotopic bladder substitution [32]:

1. Positive margins at the level of urethral dissection
2. Positive margins anywhere on the bladder specimen (in both sexes), if the primary tumour is located at the bladder neck or in the urethra (in women), or if tumour extensively infiltrates the prostate.

Pre-operative bowel preparation is not mandatory.

Before cystectomy, the patient should be counselled adequately regarding all possible alternatives, and the final decision should be based on a consensus between patient and surgeon.

For patients with inoperable locally advanced tumours (T4b), primary radical cystectomy is a palliative option and not recommended as a curative treatment.

Neoadjuvant Radiotherapy in Muscle-Invasive Bladder Cancer [33]

Pre-operative radiotherapy does not increase the survival for operable muscle invasive bladder cancer.

Bladder-Sparing Treatments

Radical TURBT

Radical TURBT is not recommended except in a rare situation when patient not willing for open surgery or unfit for radical cystectomy [34].

External beam radiotherapy [35, 36]

External beam radiotherapy alone should only be considered as a therapeutic option when the patient is unfit for cystectomy or a multimodality bladder-preserving approach. Radiotherapy can also be used to stop bleeding from the tumour when local control cannot be achieved by transurethral manipulation because of extensive local tumour growth.

Chemotherapy [37,38]

Although cisplatin-based chemotherapy, as primary therapy for locally advanced tumours in highly selected patients, has led to complete and partial local responses, the long-term success rate is low.

Multimodality treatment [39,40]

There are comparable long-term survival rates in cases of multimodality treatment success. Delay in surgical therapy can compromise survival rates.

Adjuvant Chemotherapy [41]

Adjuvant chemotherapy is advised within clinical trials, but not for routine use.

Metastatic Disease [42 -47]

Urothelial carcinoma is a chemosensitive tumour. Performance status (PS) and the presence or absence of visceral metastases are independent prognostic factors for survival.

These factors are at least as important as the type of chemotherapy administered. Cisplatin-containing combination chemotherapy is able to achieve a median survival of up to 14 months, with long-term disease-free survival reported in about 15% of patients with nodal disease and good PS. Single-agent chemotherapy provides low response rates of usually short duration. Post-chemotherapy surgery after a partial or complete response may contribute to long-term disease-free survival. Prognostic factors should guide the treatment selection.

NOTE : All chemotherapeutic drugs/ targeted therapy should be decided and administered in consultation with a Urologist.

First-line treatment for “fit” patients:

Use cisplatin-containing combination chemotherapy with GC, MVAC, preferably with GCSF, or HD-MVAC with GCSF.

Carboplatin and non-platinum combination chemotherapy is not recommended.

First-line treatment in patients ineligible ('unfit') for cisplatin:

Use carboplatin combination chemotherapy or single agents.

For cisplatin-ineligible patients ('unfit') with either PS 2 or impaired renal function, or with poor prognostic factors, first-line treatment is carboplatin-containing combination chemotherapy, preferably with gemcitabine/carboplatin.

Second-line treatment:

In patients progressing after platinum-based combination chemotherapy for metastatic disease vinflunine should be offered, which has the highest level of evidence to date, or clinical trials of other treatments.

Follow-up for non-muscle invasive bladder tumours [48, 49]

Patients with non-muscle invasive bladder tumours need to be regularly followed up because of the risk of recurrence and progression; however, the frequency and duration of cystoscopies should reflect the individual patient's degree of risk.

The result of the first cystoscopy after TUR at 3 months is a very important prognostic factor for recurrence and for progression. The first cystoscopy should thus always be performed at 3 months after TUR in all patients with non-muscle invasive bladder tumour.

Recommendations for follow-up cystoscopy

Patients with tumours at low risk of recurrence and progression should have a cystoscopy at 3 months. *If negative, the following cystoscopy is advised at 9 months and consequently yearly for 5 years.*

Patients with tumours at high risk of progression should have a cystoscopy and urinary cytology at 3 months. If negative, the following cystoscopies and cytologies should be repeated every 3 months for a period of 2 years, every 4 months in the third year, every 6 months thereafter until 5 years, and yearly thereafter. A yearly evaluation of the upper tract by IVU or retrograde pyelogram is recommended.

Patients with intermediate-risk of progression (about one-third of all patients) should have an in-between follow-up scheme using cystoscopy and cytology, adapted according to personal and subjective factors.

Patients with Tis should be followed up for life due to the high risk of recurrence and progression, both within the bladder and extravesically. Urine cytology together with cystoscopy (and bladder biopsies in cytology positive cases) is essential for monitoring of treatment efficacy. The follow-up schedule is the same as for patients with high-risk tumours.

Follow up for muscle invasive bladder cancer [50]

Follow-up is based on the stage of initial tumour after cystectomy. At every visit, the following should be performed:

History, Physical examination, Serum chemistries and chest radiograph annually for pT1 disease; semiannual evaluation for patients with pT2 disease; and quarterly evaluation for patients with pT3 disease. For the last group, semiannual CT scan is recommended. Bone scan only when indicated or symptomatic. IVU can be done for upper tract surveillance when CT scan is not readily available.

After 5 years of follow-up, stop oncological surveillance and continue with functional surveillance.

Referral criteria:

- Patients with gross painless hematuria with association with high risk factors
- Patients with severe storage LUTS with or without palpable pelvic mass suggestive of bladder cancer
- Those with advanced bladder cancer and metastases

*Situation 1: At Secondary Hospital / Non-Metro Situation: Optimal Standards Of Treatment In Situations Where Technology And Resources Are Limited.

a) Clinical diagnosis: Careful evaluation of patients with gross painless hematuria, Pelvic examination for bladder masses, not useful in non-muscle invasive bladder cancers.

b) Investigations: Urine microscopy for hematuria, urine cytology for malignant urothelial cells. Ultrasound of abdomen and pelvis - to localize the cause of hematuria like renal and bladder tumours. Cystoscopy in all cases of gross hematuria and those with bothersome severe storage LUTS and positive microscopic hematuria.

c) Treatment: According to the stage of the disease.

Standard operating procedure:

- j) Inpatient:
- k) Outpatient:
- l) Daycare:

Referral criteria:

Patients with gross painless hematuria known to have bladder tumour

Positive urine dipstick or microscopic hematuria

Positive urine cytology

*Situation 2: At super specialty facility in metro location where higher end technology is available.

a) Clinical diagnosis: Evaluation of gross hematuria, positive microscopic hematuria and positive urine cytology. Pelvic examination – to look for bladder masses.

b) Investigations: All the possible investigations mentioned.

c) Treatment: According to the stage of the disease and the treatment options selected by the patient after counseling.

Standard operating procedure

- a) Inpatient
- b) Outpatient
- c) Daycare

Referral Criteria:

For diagnosis and staging – CT Urography, molecular urinary markers.

Evaluation of metastatic disease – bone scan if required.

VI. WHO DOES WHAT? AND TIMELINES

- n. Doctor – clinical diagnosis, treatment, follow-up
- o. Nurse – counseling, preoperative preparation, essential post-operative care, stoma care and follow-up
- p. Technician – Investigations and preoperative preparation.

VII. FURTHER READING / REFERENCES.

References:

1. Ploeg M, Aben KK, Kiemeny LA. The present and future burden of urinary bladder cancer in the world. *World J Urol* 2009; 27:289-293.
2. Vaidya A, Soloway MS, Hawke C, Tiguert R, Civantos F. De novo muscle invasive bladder cancer: is there a change in trend? *J Urol* 2001 Jan;165(1):47-50.
3. Gandini S, Botteri E, Iodice S, et al. Tobacco smoking and cancer: a meta-analysis. *Int J Cancer* 2008 Jan;122(1):155-64.
4. Kogevinas M, t'Mannetje A, Cordier S, et al. Occupation and bladder cancer among men in Western Europe. *Cancer Causes and Control* 2003 Dec;14(10):907-14.
5. Chrouser K, Leibovich B, Bergstralh E, et al. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. *J Urol* 2006 Jul;174(1):107-10.
6. Gouda I, Mokhtar N, Bilal D, et al. Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. *J Egypt Natl Canc Inst* 2007 Jun;19(2):158-62.
7. Mariappan P, Zachou A, Grigor KM. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. *Eur Urol* 2010 May;57(5):843-9.
8. Kulkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. *Eur Urol* 2010 Jan;57(1):60-70.
- 9., Hungerhuber E, Stepp H, Kriegmair M, Stief Ch, Hofstetter A, Hartmann A, Knuechel R, Karl A, Tritschler S, Zaak D. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. *Urology* 2007 Feb;69(2):260-4.
10. Goessl C, Knispel HH, Millar K, et al. Is routine excretory urography necessary at first diagnosis of bladder cancer? *J Urol* 1997 Feb;157(2):480-1.
11. Fossa SD, Ous S, Berner A. Clinical significance of the 'palpable mass' in patients with muscle infiltrating bladder cancer undergoing cystectomy after pre-operative radiotherapy. *Br J Urol* 1991 Jan; 67(1):54-60.
12. Nolte-Ernsting C, Cowan N. Understanding multislice CT urography techniques: many roads lead to Rome. *Eur Radiol* 2006 Dec;16(12):2670-86.
13. Sobin LH, Gospodariwicz M, Wittekind C (eds). TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edn. Wiley-Blackwell, 2009 Dec; pp. 262-265.
14. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. *Am J Surg Pathol* 1998 Dec;22(12):1435-48.
15. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. *J Urol* 2000 Sep;164(3 Pt 1):680-4.
16. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. *Eur Urol* 2006 Mar;49(3):466-5.

17. Griffiths TRL, Charlton M, Neal DE, et al. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. *J Urol* 2002 Jun;167(6):2408-12.
18. Takenaka A, Yamada Y, Miyake H, et al. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. *Int J Urol* 2008 Apr;15(4):309-13.
19. Van Gils-Gielen RJ, Witjes WP, Caris CT, et al. Risk factors in carcinoma in situ of the urinary bladder. *Urology* 1995 Apr;45(4):581-6.
20. Brausi M, Collette L, Kurth K, et al; EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence Rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. *Eur Urol* 2002 May;41(5):523-31.
21. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. *J Urol* 2004 Jun;171(6 Pt 1):2186-90.
22. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. *J Urol* 2002 Nov;168(5):1964-70.
23. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. *J Urol* 2000 Apr;163(4):1124-9.
24. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumours. *J Urol* 2003 May;169(5):1706-8.
25. Sylvester RJ, van der Meijden APM, Witjes JA, et al. Bacillus Calmette-Guerin versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. *J Urol* 2005 Jul;174(1):86-92.
26. Shariat SF, Palapattu GS, Amiel GE, et al. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. *Urology* 2006 Sep;68(3):538-42.
27. Sherif A HL, Rintala E, Mestad O, et al. Nordic Urothelial Cancer Group. Downstaging and pathoanatomical outcome following neoadjuvant cisplatin based combination chemotherapy for muscle-invasive bladder carcinoma: An analysis of selected patients from two combined randomised prospective Nordic trials. *Urology* 2006;68(Suppl 1):137, MP-1307.
28. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. *Lancet* 2003 Jun;361(9373):1927-34.
29. World Health Organization (WHO) Consensus Conference in Bladder Cancer, Hautmann RE, Abol-Enein H, Hafez K, Haro I, Mansson W, Mills RD, Montie JD,

Sagalowsky AI, Stein JP, Stenzl A, Studer UE, Volkmer BG. Urinary diversion. *Urology* 2007 Jan;69(1 Suppl):17-49.

30. Leissner J, Hohenfellner R, Thuroff JW, et al. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. *BJU Int* 2000 May;85(7): 817-23.

31. Chang SS, Hassan JM, Cookson MS, et al. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. *J Urol* 2003 Oct;170(4 Pt 1):1085-7.

32. Hautmann RE, Volkmer BG, Schumacher MC, et al. Long-term results of standard procedures in urology: the ileal neobladder. *World J Urol* 2006 Aug;24(3):305-14.

33. Widmark A, Flodgren P, Damber JE, et al. A systematic overview of radiation therapy effects in urinary bladder cancer. *Acta Oncol* 2003;42(5-6):567-81.

34. Whitmore WF Jr, Batata MA, Ghoneim MA, et al. Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. *J Urol* 1977 Jul;118(1 Pt 2):184-7.

35. Gospodarowicz MK, Hawkins NV, Rawlings GA, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. *J Urol* 1989 Dec;142(6):1448-53; discussion 1453-4.

36. Gospodarowicz MK, Quilty PM, Scalliet P, et al. The place of radiation therapy as definitive treatment of bladder cancer. *Int J Urol* 1995 Jun;2(Suppl 2):41-8.

37. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med* 2003 Aug 28;349(9):859-66.

38. Kachnic LA, Kaufman DS, Heney NM, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. *J Clin Oncol* 1997 Mar;15(3):1022-9.

39. Shipley WU, Kaufman DS, Heney NM, et al. An update of selective bladder preservation by combined modality therapy for invasive bladder cancer. *Eur Urol* 1998;33 Suppl 4:32-4.

40. Sánchez-Ortiz RF, Huang WC, Mick R, et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. *J Urol* 2003 Jan;169(1):110-5.

41. Lehmann J, Retz M, Wiemers C, et al; AUO-AB 05/95. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). *J Clin Oncol* 2005 Aug;23(22):4963-74.

42. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. *J Clin Oncol* 1992 Jul;10(7):1066-73.

43. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. *J Clin Oncol* 1990 Jun;8(6):1050-5.

44. Sternberg CN, de Mulder P, Schornagel JH, et al; EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus

- classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006 Jan;42(1):50-4.
45. Bellmunt J, Ribas A, Eres N, et al. Carboplatinbased versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997 Nov;80(10):1966-72.
46. Nogué-Aliguer M, Carles J, Arrivi A, et al; Spanish Cooperative Group. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 2003 May;97(9):2180-6.
47. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol 2009 Nov 20;27(33):5634-9.
48. Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 2002 Apr;167(4):1634-7.
49. Mariappan P, Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 2005 Apr;173(4):1008-11.
50. Slaton JW, Swanson DA, Grossman HB, Dinney CP. A stage specific approach to tumour surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1999 Sep;162(3 Pt 1):710-4.

RESOURCES REQUIRED FOR ONE PATIENT /PROCEDURE (PATIENT WEIGHT 60 KGS)
 (Units to be specified for human resources, investigations, drugs and consumables and equipment. Quantity to also be specified)

| Situation | HUMAN RESOURCES | INVESTIGATIONS | DRUGS & CONSUMABLES | EQUIPMENT |
|-----------|-----------------|----------------|---------------------|-----------|
| 1 | | | | |
| 2 | | | | |

PROSTATE CANCER

I. WHEN TO SUSPECT / RECOGNIZE?

- Introduction and Case definition: Cancer of the prostate (PCa) is now recognized as one of the most important medical problems facing the male population.[1] Prostate cancer is the 2nd most common cause of cancer death in men. Affects 4% of men in undeveloped countries & 15% of men in developed countries [2]
- Risk factors
 - Increasing age
 - Ethnical origin
 - Heredity
- Risk is doubled when one first line relative has prostate cancer. Risk is 5 – 11 fold when two or more first line relatives has PCa[3]

II. INCIDENCE OF THE CONDITION IN OUR COUNTRY: Exact incidence is unknown. Expected to be of same incidence as the western world.

III DIFFERENTIAL DIAGNOSIS:

- m) Benign prostatic hyperplasia
- n) Granulomatous Prostatitis
- o) Transitional cell carcinoma of prostate
- p) Chronic prostatitis
- q) Prostatic calculi

IV. PREVENTION AND COUNSELING:

- d) Mass education about prostate cancer
- e) Opportunistic screening for prostate cancer with serum PSA
- f) Counseling about serum PSA and its implications
- g) Chemoprevention of prostate cancer
- h) Recognizing bladder outflow obstruction and other complications in men due to prostate cancer
- i) Thorough examination in elderly men who are at risk
- j) Prompt referral of men with suspicion of prostate cancer to higher centres for further evaluation

V. OPTIMAL DIAGNOSTIC CRITERIA, INVESTIGATIONS, TREATMENT & REFERRAL CRITERIA

Diagnostic criteria: Screening & Early detection of prostate cancer

Population or mass screening is defined as the examination of asymptomatic men (at risk). It usually takes place as part of a trial or study and is initiated by the screener. In contrast, early detection or opportunistic screening comprises individual case findings, which are initiated by the person being screened (patient) and/or his physician. The primary endpoint of both types of screening has two aspects:

1. Reduction in mortality from PCa.
2. Quality-of-life adjusted gain in life years (QUALYs).

Screening for prostate cancer has conflicting results.

Based on the results of two large, randomised trials [4,5], it is accepted that at present widespread mass screening for PCa is not appropriate. Rather, early detection (opportunistic screening) should be offered to the well-informed man. Hence

- Early PSA testing should be a shared decision between patient and physician
- PSA testing & DRE – offered to men >40 years of age & expected life expectancy of at least 10 years

Diagnosis –The main diagnostic tools to obtain evidence of PCa include digital rectal examination (DRE), serum concentration of PSA and transrectal ultrasonography (TRUS).

Investigations:

1. DRE: Most prostate cancers are located in the peripheral zone of the prostate and may be detected by DRE when the volume is about 0.2 mL or larger. A suspect DRE is an absolute indication for prostate biopsy. In about 18% of all patients, PCa is detected by a suspect DRE alone, irrespective of the PSA level [6]
2. Serum PSA(Prostate-specific antigen) is organ-specific but not cancer-specific. Thus, serum levels may be elevated in the presence of benign prostatic hypertrophy (BPH), prostatitis and other non-malignant conditions. The level of PSA as an independent variable is a better predictor of cancer than suspicious findings on DRE or TRUS [7]. The level of PSA is a continuous parameter: the higher the value, the more likely is the existence of PCa. This means there is no universally accepted cut-off or upper limit.[8] As yet, there is no long-term data to help determine the optimal PSA threshold value for detecting non-palpable, but clinically significant, PCa. Modifications to improve the specificity of PSA in early detection of Ca.P
 - a. PSA density
 - b. PSA density of transition zone
 - c. Age specific PSA
 - d. PSA molecular forms – PCA3
 - e. Free / Total PSA ratio (at PSA 4-10ng/ml) <0.10 – 56% biopsy positive
 - f. PSA doubling time (PSADT)
 - g. PSA velocity
 - h. When in doubt, repeat PSA under standardised conditions
3. Transrectal ultrasound of prostate (TRUS) guided biopsy of prostate. Gray-scale TRUS does not detect areas of PCa with adequate reliability. It is therefore not useful to replace systematic biopsies with targeted biopsies of suspect areas.

However, additional biopsies of suspect areas may be useful. Transrectal ultrasonography (TRUS) guided biopsy under antibiotic cover with periprostatic nerve block– minimum 10 core laterally and posteriorly directed biopsy is recommended (>12 not significantly more conclusive). [9]The indications for a repeat biopsy (including TZ biopsy) [10] are:

- a. Rising and/or persistent PSA, suspicious DRE;
- b. Atypical small acinar proliferation (ASAP).
- c. Extensive High-grade prostatic intraepithelial neoplasia (PIN)

Complications of biopsy – infection, sepsis < 1%, clot retention, acute urinary retention, bleeding from rectum, hematuria, hemospermia (the last 3 are mostly self limiting).

- d. Pathology of prostate cancer:
 - i. The Gleason score is the sum of the most dominant and second most dominant (in terms of volume) Gleason grade.
 - ii. A diagnosis of Gleason score 4 or lower should not be given on prostate biopsies
 - iii. Gleason score system is the single strongest prognostic factor for clinical behaviour and treatment response.

4. TRUS is also useful for staging of prostate cancer, however remains inadequate. [11]
5. MRI – abdomen and pelvis/ MR Urography [12] (risk stratification)
 - a. Local staging (T-staging)
 - b. MRI demonstrates higher accuracy for the assessment of uni- or bilobar disease (T2), Extracapsular extension (ECE) and Seminal vesicle invasion (SVI) (T3), as well as the invasion of adjacent structures (T4).
 - c. Lymph node status (N-staging) is only important when potentially curative treatment is planned.
6. Pelvic lymph node dissection remains the only reliable staging method in clinically localized PCa. [13]
7. Bone scan - Skeletal metastasis (M-staging) is best assessed by bone scan. This may not be indicated in asymptomatic patients if the serum PSA level is less than 20 ng/mL (risk stratification) in the presence of well or moderately differentiated tumours.[14]
8. Serum alkaline phosphatase – if elevated, indicates metastatic bone disease.
9. Transurethral resection of prostate- In those men who come with bladder outflow obstruction in an unsuspected fashion and biopsy report may reveal carcinoma of prostate.

Staging of prostate cancer: Based on Tumour Node Metastasis (TNM) classification of carcinoma prostate [15].

- **T - primary tumour**
- TX Primary tumour cannot be assessed
- T0 No evidence of primary tumour

- T1 Clinically inapparent tumour not palpable or visible by imaging
 - T1a Tumour incidental histological finding in 5% or less of tissue resected
 - T1b Tumour incidental histological finding in more than 5% of tissue resected
 - T1c Tumour identified by needle biopsy (e.g. because of elevated prostate-specific antigen [PSA] level)
- T2 Tumour confined within the prostate¹
 - T2a Tumour involves one half of one lobe or less
 - T2b Tumour involves more than half of one lobe, but not both lobes
 - T2c Tumour involves both lobes
 - T3 Tumour extends through the prostatic capsule
 - T3a Extracapsular extension (unilateral or bilateral) including microscopic bladder neck involvement.
 - T3b Tumour invades seminal vesicle(s)
 - T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: external sphincter, rectum, levator muscles, and/or pelvic wall
- **N - regional lymph nodes**
 - NX Regional lymph nodes cannot be assessed
 - N0 No regional lymph node metastasis
 - N1 Regional lymph node metastasis
- **M - distant metastasis**
 - MX Distant metastasis cannot be assessed
 - M0 No distant metastasis
 - M1 Distant metastasis
 - M1a Non-regional lymph node(s)
 - M1b Bone(s)
 - M1c Other site(s)
- Group I T1a-c N0 M0 PSA < 10 Gleason < 6
 - T2a N0 M0 PSA < 10 Gleason < 6
- Group IIA T1a-c N0 M0 PSA < 20 Gleason 7
 - T1a-c N0 M0 PSA > 10 < 20 Gleason < 6
 - T2a, b N0 M0 PSA < 20 Gleason < 7
- Group IIb T2c N0 M0 Any PSA Any Gleason
 - T1-2 N0 M0 PSA > 20 Any Gleason
 - T1-2 N0 M0 Any PSA Gleason > 8
- Group III T3a, b N0 M0 Any PSA Any Gleason
- Group IV T4 N0 M0 Any PSA Any Gleason
 - Any T N1 M0 Any PSA Any Gleason
 - Any T Any N M0 Any PSA Any Gleason
- (Note: When either PSA or Gleason is not available, grouping should be determined by cT category and whichever of either PSA or Gleason is available. When neither is available prognostic grouping is not possible, use stage grouping)

Treatment: Treatment of prostate cancer depends on the stage of the disease and prognostic information available.

- **Deferred treatment (Watchful waiting & Active surveillance) [16- 20]**

Make difference between active surveillance and watchful waiting

Indications:

- **In presumed localisedPCa (Nx-N0, M0):**
 - **Stage T1a:** well and moderately differentiated tumours. In younger patients with a life expectancy of > 10 years, re-evaluation with PSA, TRUS and biopsies of the prostatic remnant is recommended
 - **Stage T1b-T2b:** well & moderately differentiated tumours. In asymptomatic patients with a life expectancy of < 10 years
 - **Inclusion criteria for active surveillance** with the lowest risk of cancer progression are:
 - PSA < 10 ng/ml, biopsy Gleason score < 6, < 2 positive biopsies, < 50% cancer per biopsy, cT1c-2a
- **In presumed localisedPCa (Nx-N0, M0):**
 - Stage T1b-T2b patients who are well informed and have well-differentiated (or Gleason 2-4) PCa and a life expectancy of 10-15 years.
 - All patients not willing to accept side-effects of active treatment.
 - Well-informed, asymptomatic patients with high PSA levels for whom cure is unlikely.
- **In locally advanced disease (stage T3-T4):**
 - Asymptomatic patients with well- or moderately differentiated cancer, PCa and a short life expectancy
 - PSA < 50 ng/mL and PSA doubling time > 12 months
- **In metastatic disease (M1):**
 - A very rare patient without any symptoms and the possibility of close follow-up

The criteria for active surveillance have not reached a consensus stage yet. Every institution has different parameters and that should be mentioned. Active surveillance is not the same as watchful waiting.

2. Radical Prostatectomy [21,22]period between biopsy and surgery

- **Indications**
 - In patients with low and intermediate risk localisedPCa (cT1a-T2b and Gleason score 2-7 and PSA < 20) and a life expectancy > 10 years
- **Optional**
 - Selected patients with low-volume high-risk localisedPCa (cT3a or Gleason score 8-10 or PSA >20)
 - Highly selected patients with very high-risk localisedPCa (cT3b-T4 N0 or any T N1) in the context of multimodality treatment

- **Recommendations**
 - Short-term (3 months) neoadjuvant therapy with gonadotrophin releasing-hormone analogues is not recommended in the treatment of stage T1-T2 disease
 - Nerve-sparing surgery may be attempted(offered) in pre-operatively potent patients with low risk for extracapsular disease (T1c, Gleason score < 7 and PSA < 10 ng/mL or see Partin tables / nomograms)
 - Unilateral nerve-sparing procedures are an option in stage T2a disease
 - Recommendation for Lymphadenectomy
 - Extended PLND is recommended for all patients who have a greater than 2% chance of having lymph node disease. (NCCN guidelines)

3. Definitive radiation therapy [23-28]

- **In localised prostate cancer T1c-T2c N0 M0**, 3D-CRT with or without IMRT is recommended even for young patients who refuse surgical intervention. There is fairly strong evidence that low-, intermediate- and high-risk patients benefit from dose escalation
- **For patients in the high-risk group**, short-term ADT prior to and during radiotherapy results in increased overall survival, but three years of adjuvant ADT are better according to the results of EORTC 22961
- Transperineal interstitial brachytherapy with permanent implants is an option for
 - Patients with cT1-T2a, Gleason score < 7 (or 3 + 4), PSA < 10 ng/mL, prostate volume < 50 mL, without a previous TURP and with a good IPSS
- Immediate post-operative external irradiation after RP for
 - Patients with pathological tumour stage T3 N0 M0 improves overall survival, biochemical and clinical disease-free survival with the highest impact in cases of positive margins (R1)
- An alternative option is to give radiation at the time of biochemical failure, but before PSA rises above 0.5 ng/mL
- In locally advanced prostate cancer T3-4 N0 M0, overall survival is improved by concomitant and adjuvant hormonal therapy for a total duration of 3 years, with external beam irradiation for patients with a WHO 0-2 performance status.
- For a subset of patients with T2c-T3 N0-x and a Gleason score of 2-6, short-term ADT before and during radiotherapy may favourably influence overall survival
- In very high-risk prostate cancer, c-pN1 M0 with no severe co-morbidity, pelvic external irradiation and immediate long-term adjuvant hormonal treatment improve overall survival, disease-specific failure, metastatic failure and biochemical control

4. Experimental local treatment of prostate cancer[29-32]under investigations

- **Cyrosurgery:**

- Patients with low-risk PCa (PSA < 10 ng/mL, < T2a, Gleason score < 6) or intermediate-risk PCa (PSA > 10 ng/mL, or Gleason score > 7, or stage > 2b) represent potential candidates for CSAP.
- Prostate size should be < 40 mL at the time of therapy.
- Long-term results are lacking, while 5-year biochemical progression free rates are inferior to those achieved by RP in low risk patients. Patients must be informed accordingly.
- Cryosurgery - a possible alternative treatment for PCa in patients who are unfit for surgery or with a life expectancy < 10 years.
- All other minimally invasive treatment options – such as HIFU microwave and electrosurgery – are still experimental or investigational.
- Focal therapy of PCa is still in its infancy and cannot be recommended as a therapeutic alternative outside clinical trials

r) Hormonal therapy[33-4]

Bone densitometry and bisphosphonates

17. In advanced PCa, androgen deprivation therapy (ADT)
 18. delays progression,
 19. prevents potentially catastrophic complications, and
 20. palliates symptoms effectively, but does not prolong survival.
21. In advanced PCa, all forms of castration used as monotherapy (e.g. orchiectomy, LHRH and DES) have equivalent efficacy.
22. Non-steroidal anti-androgen monotherapy (e.g. bicalutamide) is an alternative to castration in patients with locally advanced disease.
23. In metastatic PCa, the addition of a non-steroidal anti-androgen to castration (CAB) results in a small advantage in OS over castration alone, but is associated with increased adverse events, reduced QoL, and high costs.
24. Intermittent ADT should no longer be regarded as experimental, even though long-term data from prospective clinical trials are still awaited. ‘Minimal’ ADT should, however, continue to be seen as experimental.
25. In advanced PCa, immediate ADT (given at diagnosis) significantly reduces disease progression, as well as the complication rate due to progression itself, compared with deferred ADT (delivered at symptomatic progression). However, the survival benefit is at best marginal and not related to cancer-specific survival.
26. Bilateral orchiectomy might be the most cost-effective form of ADT, especially if initiated after the occurrence of symptoms from metastatic disease.

Follow-up [47-50]

After treatment with curative intent

14. In asymptomatic patients, a disease-specific history & a serum PSA measurement supplemented by DRE - recommended tests for routine follow-up. These should be performed at 3, 6 & 12 months after treatment, then every 6 months until 3 years, and then annually.
15. After radical prostatectomy, a serum PSA level of more than 0.2 ng/mL can be associated with residual or recurrent disease.

16. After radiation therapy, a rising PSA level over 2 ng/mL above the nadir PSA, rather than a specific threshold value, is the most reliable sign of persistent or recurrent disease.
17. Both a palpable nodule and a rising serum PSA level can be signs of local disease recurrence
18. Detection of local recurrence by TRUS and biopsy is only recommended if it will affect the treatment plan.
19. In most cases TRUS and biopsy are not necessary before second-line therapy.
20. Metastasis may be detected by pelvic CT/MRI or bone scan. In asymptomatic patients, these examinations may be omitted if the serum PSA level < 120 ng/mL.
21. Routine bone scans & other imaging studies are not recommended in asymptomatic patients. If a patient has bone pain, a bone scan should be considered irrespective of the serum PSA level.

After hormonal therapy [51-53]

- Patients should first be evaluated at three & six months after the initiation of treatment. (one month and 3 months after initiating treatment)
- As a minimum,
 - serum PSA measurement
 - digital rectal examination (DRE),
 - serum testosterone and careful evaluation of symptoms in order to assess the treatment response and the side-effects of the treatments given.
- Follow-up should be tailored for the individual patient, according to symptoms, prognostic factors and the treatment given.
- In patients with stage M0 disease with a good treatment response, follow-up is scheduled every six months, and should include as a minimum a disease-specific history, DRE and serum PSA determination
- In patients with stage M1 disease with a good treatment response, follow-up is scheduled for every three to six months.
- As a minimum, this should include a disease-specific history, DRE and serum PSA determination, and is frequently supplemented with haemoglobin, serum creatinine and alkaline phosphatase measurements.
- Patients (especially if M1b status) should be advised on the clinical signs that could suggest spinal cord compression
- When disease progression occurs, or if the patient does not respond to the treatment given, the follow-up needs to be individualised
- Routine imaging of stable patients is not recommended

Treatment of biochemical failure after treatment with curative intent [54- 61]

Presumed local failure after radical prostatectomy

- Patients with presumed local failure only may be candidates for salvage radiotherapy. At least 64 Gy given and preferably before PSA has risen above 0.5 ng/mL.
- Other patients are best offered a period of watchful waiting (active monitoring), with possible hormonal therapy later on

- Presumed local failure after radiotherapy
 - Selected patients may be candidates for salvage radical prostatectomy and patients should be informed about the higher risk of complications, such as incontinence and erectile dysfunction.
 - Salvage prostatectomy should only be performed in experienced centres. Other patients are best offered a period of watchful waiting (active monitoring), with possible hormonal therapy later on
- Presumed distant failure
 - There is some evidence that early hormonal therapy may be of benefit in +/- local failure, delaying progression, and possibly achieving a survival benefit in comparison with delayed therapy.
 - Local therapy is not recommended except for palliative reasons

Castration refractory prostate cancer (CRPC or HRPC)-

- **Definition:**
 - Serum castration levels of testosterone (testosterone < 50 ng/dL or < 1.7 nmol/L)
 - Three consecutive rises of PSA, 1 week apart, resulting in two 50% increases over the nadir, with a PSA > 2 ng/mL
 - Anti-androgen withdrawal for at least 4 weeks*
 - PSA progression, despite consecutive hormonal manipulations†
 - * Either anti-androgen withdrawal or one secondary hormonal manipulation should have been done in order to fulfil the criteria for CRPC.
 - † Progression of osseous lesions: progression or appearance of two or more lesions on bone scan or soft tissue lesions using RECIST (Response Evaluation Criteria in Solid Tumours) and with nodes > 2 cm in diameter.

CRPC-

Recommendation of treatment after hormonal treatment

- It is recommended to stop anti-androgen therapy once PSA progression is documented
- Four to six weeks after discontinuation of flutamide or bicalutamide, an eventual anti-androgen withdrawal effect is apparent
- No clear-cut recommendation can be made for the most effective drug for secondary hormonal manipulations. Secondary hormonal manipulations possibilities
- Abiraterone and Cabazitaxel have shown to prolong survival in CRPC after docetaxel chemotherapy. Sipuleucel T is prostate vaccine which is used and has been approved in the west for CRPC which is minimally symptomatic or asymptomatic. Not yet available in India.

Recommendation of cytotoxic therapy

26. Ideally, patients with CRPC should be counselled, managed and treated in a multidisciplinary team

27. In non-metastatic CRPC, cytotoxic therapy should only be considered in clinical trials
28. In patients with a PSA rise only, two consecutive increases of PSA serum levels above a previous reference level should be documented
29. Prior to treatment, PSA serum levels should be > 2 ng/mL to assure correct interpretation of therapeutic efficacy
30. Potential benefits of cytotoxic therapy and expected side-effects should be discussed with each individual patient
31. In patients with metastatic CRPC, and who are candidates for cytotoxic therapy, docetaxel at 75 mg/m² every 3 weeks has shown a significant survival benefit
32. In patients with symptomatic osseous metastases due to CRPC, either docetaxel or mitoxantrone with prednisone or hydrocortisone are viable therapeutic options
33. Second-line docetaxel should be considered in previously responding patients to docetaxel.
34. Otherwise, treatment is tailored to the individual patient
35. Cabazitaxel should be considered as effective second-line treatment following docetaxel
36. Chemotherapeutic drugs/ targeted therapy for cancer prostate patients should be decided and administered under supervision of a Urologist.

Recommendation of palliative management

- Patients with symptomatic and extensive osseous metastases cannot benefit from medical treatment with regard to prolongation of life
- Management of these patients has to be directed at improvement of QoL and mainly pain reduction
- Effective medical management with the highest efficacy and a low frequency of side-effects is the major goal of therapy
- Bisphosphonates may be offered to patients with skeletal masses (mainly zoledronic acid has been studied) to prevent osseous complications. However, the benefits must be balanced against the toxicity of these agents, in particular jaw necrosis must be avoided
- Palliative treatments such as radionuclides, external beam radiotherapy, adequate use of analgesics should be considered early in the management of painful osseous metastases
- Spinal surgery or decompressive radiotherapy are emergency surgeries which have to be considered in patients with neurological symptoms might be an emergency

Denosumab is more efficacious in preventing skeletal related events than Zoledronic acid with no need to adjust dose for mild to moderate renal dysfunction

Referral criteria for Urologist :

- Men who come with LUTS with DRE showing hard nodular prostate
- Localized prostate cancer
- Men with advanced prostate cancer / metastases

***Situation 1: At Secondary Hospital / Non-Metro Situation: Optimal Standards Of Treatment In Situations Where Technology And Resources Are Limited.**

a) Clinical diagnosis: Hard, nodular, asymmetric prostatic enlargement in digital rectal examination.

b) Investigations: Ultrasound of abdomen and pelvis (preferably by trans rectal ultrasound) – to assess the size and echotexture of prostate and to assess the tumour factors.

c) Treatment: According to the stage of the disease.

Standard operating procedure:

Inpatient:
Outpatient
Daycare:

Referral criteria:

Men who come with LUTS with DRE showing hard nodular prostate
Localized prostate cancer
Men with advanced prostate cancer / metastases

***Situation 2: At super speciality facility in metro location where higher end technology is available.**

a) Clinical diagnosis: DRE and look for metastatic lesions.

b) Investigations: All the possible investigations mentioned.

c) Treatment: According to the stage of the disease and the treatment options selected by the patient after counseling.

Standard operating procedure

a) Inpatient
b) Outpatient
c) Daycare

Referral Criteria:

For diagnosis and staging – TRUS guided biopsy of prostate (depending on centers of excellence)

Evaluation of metastatic disease – bone scan

Extensive metastatic disease requiring advanced speciality care like radiopharmaceuticals, spine decompression surgery and neurosurgery.

VI. WHO DOES WHAT? AND TIMELINES

- q. Doctor – clinical diagnosis, treatment
- r. Nurse – counseling, Preoperative preparation, essential post-operative care.
- s. Technician – Investigations like serum PSA, bone scan and for administering treatment like radiopharmaceuticals.

VII. FURTHER READING / REFERENCES.

References:

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. *Ann Oncol* 2005 Mar;16(3):481-8.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. *CA Cancer J Clin* 2008 Mar;58(2):71-96.
3. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. *Prostate* 1990;17(4):337-47.
4. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med* 2009 Mar 26;360(13):1310-9.
5. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009 Mar 26;360(13):1320-8.
6. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. *Urology* 1993 Oct;42(4):365-74.
7. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. *J Urol* 1994 May;151(5):1283-90.
8. Stamey TA, Freiha FS, McNeal J, Redwine EA, Whittemore AS, Schmid H-P. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. *Cancer* 1993 Feb;71(3 Suppl):933-8.
9. Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, et al; ProtecT Study Group. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. *Health Technol Assess* 2003;7(14):1-88.
10. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. *J Urol* 2006 Mar;175(3 Pt 1):820-834.

11. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Detection of clinical unilateral T3a prostate cancer – by digital rectal examination or transrectal ultrasonography? *BJU Int* 2006 Nov;98(5):982-5.
12. Mitterberger M, Pinggera GM, Pallwein L, Gradl J, Frauscher F, Bartsch G, Strasser H, Akkad T, Horninger W. The value of three-dimensional transrectal ultrasonography in staging prostate cancer. *BJU Int* 2007 Jul;100(1):47-50.
13. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? *J Urol* 2002 Aug;168(2):514-18, discussion 518.
14. Soloway MS, Hardemann SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M. Stratification of patients with metastatic prostate cancer based on the extent of disease on initial bone scan. *Cancer* 1988 Jan;61(1):195-202.
15. Sobin LH, Gospodariwicz M, Wittekind C (eds). *TNM classification of malignant tumors*. UICC International Union Against Cancer. 7th edn. Wiley-Blackwell, 2009 Dec; pp. 243-248.
16. Bill-Axelsson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, et al for the Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med* 2005 May;352(19):1977-84.
17. Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. *Scand J UrolNephrolSuppl* 1995;172:65-72
18. Klotz L. Active surveillance for favorable-risk prostate cancer: who, how and why? *Nat ClinPractOncol* 2007;4(12):692-8
19. Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO. Natural history of early, localized prostate cancer. *JAMA* 2004 Jun;291(22):2713-19.
20. Adolfsson J, Steineck G, Hedlund PO. Deferred treatment of locally advanced non-metastatic prostate cancer: a long-term followup. *J Urol* 1999 Feb;161(2):505-8.
21. Bill-Axelsson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Adami HO, Johansson JE; Scandinavian Prostate Cancer Group Study Number 4. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. *J Natl Cancer Inst* 2008 Aug;100(16):1144-54
22. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. *UrolClin North Am* 2001 Aug;28(3):555-65.
23. Nilsson S, Norlen BJ, Widmarks A. A systematic overview of radiation therapy effects in prostate cancer. *ActaOncol* 2004;43(4):316-81.
24. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. *J Urol* 2006 Oct;176(4 PT 1):1415-9.
25. Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. *J ClinOncol* 2006 Nov;24(33):5298-304.

26. Kupelian PA, Potters L, Ciezki JP, Reddy CA, Reuther AM, Klein EA. Radical prostatectomy, external beam radiotherapy < 72 Gy, external radiotherapy > or = 72 Gy, permanent seed implantation or combined seeds/external beam radiotherapy for stage T1-2 prostate cancer. *Int J RadiatOncolBiolPhys* 2004 Jan;58(1):25-33.
27. Sylvester JE, Grimm PD, Blasko JC, Millar J, Orio PF 3rd, Skoglund S, Galbreath RW, Merrick G. 15-year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. *Int J RadiatOncolBiolPhys* 2007 Jan;67(1):57-64.
28. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. *J Urol* 2009 Mar;181(3):956-62
29. Beerlage HP, Thüroff S, Madersbacher S, Zlotta AR, Aus G, de Reijke TM, de la Rosette JJ. Current status of minimally invasive treatment options for localized prostate carcinoma. *EurUrol* 2000 Jan;37(1):2-13.
30. Aus G. Current status of HIFU and cryotherapy in prostate cancer—a review. *EurUrol* 2006 Nov;50(5):927-34.
31. Blana A, Walter B, Rogenhofer S, Wieland W. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. *Urology* 2004 Feb;63(2):297-300.
32. Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become standard of care for men with localized prostate cancer? *Nat ClinPractOncol* 2007 Nov;4(11):632-42.
33. McLeod DG. Hormonal therapy: historical perspective to future directions. *Urology* 2003 Feb;61(2Suppl 1):3-7.
34. Walsh PC. Physiologic basis for hormonal therapy in carcinoma of the prostate. *UrolClin North Am* 1975 Feb;2(1):125-40.
35. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. *Urology* 2000 Dec;56(6):1021-4.
36. Desmond AD, Arnold AJ, Hastie KJ. Subcapsular orchiectomy under local anaesthesia. Technique, results and implications. *Br J Urol* 1988 Feb;61(2):143-5.
37. Byar DP. Proceedings: the Veterans Administration Co-operative Urological Research Group studies of cancer of the prostate. *Cancer* 1973 Nov;32(5):1126-30.
38. Agarwal DK, Costello AJ, Peters J, Sikaris K, Crowe H. Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hypertrophy. *BJU Int* 2000 Apr;85(6):690-5.
39. Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumourigenesis. *Peptides* 1999;20(10):1247-62.
40. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. *BJU Int* 2003 Mar;91(5):455-61.

41. Moffat LE. Comparison of Zoladex, diethylstilboestrol and cyproterone acetate treatment in advanced prostate cancer. *EurUrol* 1990;18(Suppl 3):26-7.
42. Moul JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. *Cancer* 2009 Aug;115(15):3376-8.
43. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. *Cancer* 2002 Jul;95(2):361-76
44. Ornstein DK, Rao GS, Johnson B, Charlton ET, Andriole GL. Combined finasteride and flutamide therapy in men with advanced prostate cancer. *Urology* 1996 Dec;48(6):901-5.
45. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D; Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. *Lancet Oncol* 2006 Jun;7(6):472-9.
46. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. *EurUrol* 2010 Jan;57(1):49-59.
47. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancerspecific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. *UrolClin North Am* 2001 Aug;28(3):555-65.
48. Rosser CJ, Chichakli R, Levy LB, Kuban DA, Smith LG, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. *J Urol* 2002 Aug;168(2):536-41.
49. Moul JW. Prostate specific antigen only progression of prostate cancer. *J Urol* 2000 Jun;163(6):1632-42.
50. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. *Int J RadiatOncolBiolPhys* 1997 Mar;37(5):1035-41.
51. Petros JA, Andriole GL. Serum PSA after antiandrogen therapy. *UrolClin North Am* 1993 Nov;20(4):749-56.
52. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. *J Urol* 2002 Sep;168(3):995-1000.
53. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. *J Natl Cancer Inst* 2007;99:1516-24.
54. Grossfeld GD, Stier DM, Flanders SC, Henning JM, Schonfeld W, Warolin K, Carroll PR. Use of second treatment following definitive local therapy for prostate cancer: data from the CaPSURE database. *J Urol* 1998 Oct;160(4):1398-404.
55. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. *JAMA* 1999 May;281(17):1591-7.

56. Gomez P, Manoharan M, Kim SS, Soloway MS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? *BJU Int* 2004 Aug;94(3):299-302.
57. Connolly JA, Shinohara K, Presti JC Jr, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. *Urology* 1996 Feb;47(2):225-31.
58. Heidenreich A, Semrau R, Thüer D, Pfister D. Radical salvage prostatectomy: Treatment of local recurrence of prostate cancer after radiotherapy. *Urologe A* 2008 Nov;47(11):1441-6.
59. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. *J Urol* 2009 Mar;181:956-62.
60. Carroll P. Rising PSA after a radical treatment. *EurUrol* 2001;40(Suppl 2):9-16.
61. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. *JAMA* 2008 Jun;299:2760-9.
62. Isaacs JT, Coffey DS. Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. *Cancer Res* 1981 Dec;41(12 Pt 1):5070-5.
63. Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? *Cancer Cell* 2009 Dec 8;16(6):458-62.
64. Schröder FH. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. *EurUrol* 2008 Jun;53(6):1129-37.
65. Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS. The androgen axis in recurrent prostate cancer. *Clin Cancer Res* 2004 Jan;10(2):440-8.
66. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, et al; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. *J Clin Oncol* 2008 Mar;26(7): 1148-59.
67. Waselenko JK, Dawson NA. Management of progressive metastatic prostate cancer. *Oncology (Huntingt)* 1997 Oct;11(10):1551-60; discussion 1560-3, 1567-8.
68. Kelly WK, Scher HI, Mazurmdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. *J Clin Oncol* 1993 Apr;11(4):607-15.
69. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. *J Clin Oncol* 1998 May;16(5):1835-43.
70. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonates for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. *J Urol* 2001 Jan;165(1):136-40.

71. Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent disease. *Urology* 2003 Dec;62(Suppl 1):87-94.
72. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal syndrome. *J Urol* 1993 Mar;149(3):607-9.
73. McLeod DG. Antiandrogenic drugs. *Cancer* 1993 Feb;71(3 Suppl):1046-9.
74. Fowler JE Jr, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal deferred flutamide treatment. *J Urol* 1995 Aug;154(2 Pt 1):448-53.
75. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylbestrol as a second line hormonal agent in advanced prostate cancer. *Urology* 1998 Aug;52(2):257-60.
76. Danila DC, de Bono J, Ryan CJ, Denmeade S, Smith M, Taplin M, Bubley G, Molina A, Haqq C, Scher HI. Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto). *J Clin Oncol* 27:15s, 2009 (suppl; abstr 5048)
77. Fosså SD, Jacobsen AB, Ginman C, Jacobsen IN, Overn S, Iversen JR, Urnes T, Dahl AA, Veenstra M, Sandstad B. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. *Eur Urol* 2007 Dec;52(6):1691-8.
78. 110. Ryan CW, Stadler WM, Vogelzang NJ. Docetaxel and exisulind in hormone-refractory prostate cancer. *Semin Oncol* 2001 Aug;28(4 Suppl 15):56-61.
79. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. *J Clin Oncol* 1996 Jun;14(6):1756-64.
80. Laplanche A, Beuzeboc P, Lumbroso J, Massard C, Plantade A, Escudier B, Di Palma M, Bouzy J, Haddad V, Fizazi K. A phase II trial of docetaxel and samarium in patients with bone metastases from castration-refractory prostate cancer (CRPC). Abstract. *J Clin Oncol* Jun 2007;25(18S): 5122.
81. George R, Jeba J, Ramkumar G, Chacko AG, Leng M, Tharyan P. Interventions for the treatment of metastatic extradural spinal cord compression in adults. *Cochrane Database Syst Rev* 2008 Oct;8;(4):CD006716.
82. Heidenreich A, Hofmann R, Engelmann UH The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. *J Urol* 2001 Jan;165(1):136-40.

RESOURCES REQUIRED FOR ONE PATIENT /PROCEDURE (PATIENT WEIGHT 60 KGS)
 (Units to be specified for human resources, investigations, drugs and consumables and equipment. Quantity to also be specified)

| Situation | HUMAN RESOURCES | INVESTIGATIONS | DRUGS & CONSUMABLES | EQUIPMENT |
|-----------|-----------------|----------------|---------------------|-----------|
| 1 | | | | |
| 2 | | | | |

Testicular Swelling – Testicular Torsion

Prof. Nitin S. Kekre, Professor and Head
Dr. Arabind Panda, Associate Professor
Department of Urology
CMC Medical College, Vellore

General comments:

Clinical guideline are supposed to be reflections of the best currently available evidence. They have 2 parts –

- c. A systematic review of the best available evidence and the strength of that evidence.
 - I. The methodology of systematic review is important. This should be clearly stated. All relevant studies should be studied. If Indian studies are available, then they should be included. The evidence should then be ranked using a standard system e.g. levels of evidence - Oxford Centre for Evidence-based Medicine [1]. If necessary relevant focused questions can be framed in order to exactly define the purview of the exercise.
- d. Recommendations for practice based on that evidence. These should be graded according to the level of available evidence.

The standard treatment guidelines for testicular torsion fail to mention if it is based on based on current literature following a systematic review. If the literature on testicular torsion lacks well designed studies that are amenable to a structured analysis, this should be mentioned. The evidence for the statements made here should be mentioned. There is no grading of the recommendations. If due to lack of sufficient high quality evidence this document will largely be a consensus document, this should be mentioned.

Review

V. OPTIMAL DIAGNOSTIC CRITERIA, INVESTIGATIONS, TREATMENT & REFERRAL CRITERIA

Diagnostic criteria:

7. Blue dot sign – testicular appendix torsion – Unlikely to be seen in dark skin. This should be mentioned.

Investigation

The diagnosis of testicular torsion is mainly clinical as mentioned. In case of a strong suspicion of torsion testes, waiting for a USG (with or without Doppler) can result in significant delay and loss of viability.

If at all a USG is to be included in the guideline, it should be accompanied by a rider that - in case of a strong suspicion of torsion testes the USG cannot be performed within 30 minutes, scrotal exploration is recommended. It should be emphasized that by no means should be time between presentation to the surgeon and exploration in strongly suspected cases exceed 1 hour.

Treatment

It is not necessary to lay down the steps of surgery. Guidelines are not cookbooks. It is enough to recommend scrotal exploration and fixation of the contralateral testes. While fixation of the testes with in a subdartos pouch is a good technique, it is by no means the only technique.

Concluding remarks

With the above alterations, it will be suitable for publication.

References:

- Center for evidence based medicine, Oxford, UK
<http://www.cebm.net/index.aspx?o=1025>. Accessed on 1st April, 2012.